Engaging the Community

Keep the conversation going.

Our Mission
President & Chairman’s Message

Throughout our 60+ year history, The Leukemia & Lymphoma Society (LLS) has been committed to being innovative in all ways to find cures for blood cancers and improve the lives of patients and their families.

Using social media is one such innovation. Its vast reach and immediacy provide a better way for people to connect and has changed the way we communicate in our daily lives. We saw its potential as a way to efficiently connect more directly with our patients, friends and supporters early on when we created the LLS blog and transferred our discussion boards to our own social network over two years ago.

In the past year, we decided to more fully capitalize on this growing and effective communications venue. We realized that expanding our social media network would help us more fully engage all members of the LLS community while showcasing www.lls.org, our National website. People interact online – “posting,” “tweeting,” “following,” “liking” and “chatting” every day, and it made sense for us to do likewise. So we added new blogs, expanded our discussion boards, enhanced our webcast series and increased our presence on popular social networking sites such as Facebook, Twitter and YouTube.

We’re proud to say that our efforts have paid off. As this year’s Annual Report shows, our expanded social networking presence has made a difference in the key areas of Patient Services, Fundraising, Advocacy and Research. Visit our online community and you’ll see cancer patients and survivors interacting on discussion boards, “commenting” on our Facebook Fan Pages, “retweeting” our Twitter posts, and blogging on a myriad of cancer-related topics.

Social media lets us reach the LLS community faster and more efficiently than ever before. We are where you are. Together, we will continue to make progress in our fight against blood cancers.
First Connection is an amazing resource.
I remember last year feeling so lost and I received a call from someone who was about 52 when she got ALL. She’s been cancer-free for over 12 years!
I have her name and number tucked in my notebook and am so thankful for that phone call.

Commenting on the LLS blog post, “First Connection, Lasting Friendships”
Social media combines the vast reach of a massive audience with the intimacy of a personal conversation. Used extensively by our Home Office and chapters throughout the US and Canada to support the LLS community, it also provides efficient channels for our patients, fundraisers, researchers and supporters to correspond quickly and easily with each other.

People with similar interests and issues can “talk” to each other whenever and wherever they like — whether it’s galvanizing support nationwide to affect legislation, promoting a local LLS fundraiser, or discussing how to cope with treatment side effects — social media moves our mission forward. Fiscal year 2010 saw a 56% increase in the size of our social networking community, which now exceeds 1.7 million contacts. When you consider that each person, on average, is linked into several other online networks, you understand the potential of what can be accomplished by keeping our online community engaged.

In addition to expanding our social media presence on the leading networks, we’ve enhanced our own social network (located at community.lls.org). The blogs we host there (The LLS Blog, @LLS Blog, and Team In Training Blog) serve as the foundation for a communications program which reports on the latest research breakthroughs while it celebrates stories from our community. Just as important, social media gives everyone touched by cancer the opportunity to communicate, share and support one another, because we believe no one should have to fight this disease alone.

The Word from our Patient Services Community

We have expanded our social media presence to let LLS patients and their caregivers more readily connect with our many patient support resources.

The LLS Blog, The Blood Cancer Discussion Boards, our LLS Facebook Fan Page, and our chat series let patients interact candidly about what they’re going through with others who are going, or have been, through the same experience themselves. They can ask questions about specific treatments, inspire others with words of encouragement, offer support, and share the joys as well as the “bumps” on the road to recovery.

Our updated Blood Cancer Discussion Boards make it easier for participants to read and post messages on a wide range of issues. Several discussion threads offer peer-to-peer forums on topics such as “Waiting for a Diagnosis,” “My Child Has Cancer,” and “Living With…” discussions of specific blood cancers. In addition, participants can now personalize their LLS Community homepage (community.lls.org) to display the discussions they prefer, create their own blog and tag content so that others can more readily find pertinent topics.

We now have nearly 2,500 online blood cancer discussions, with more than 7,000 active participants helping hundreds of patients and their families get the support they need, because even a few words of encouragement can mean so much to those battling cancer.
The Talk from our Fundraising Community

What better way to spread the word about our hundreds of fundraising activities than by going directly where most of our donors can be found – ONLINE!

> Gap Give and Get Promotion
LLS was included in three Gap Give and Get Promotions in fiscal year 2010. For 4 days in August and November 2009, and March 2010, we were given a 30% discount coupon from Gap, with 5% of the sales from each customer using the coupon going to LLS. Each Gap Promotion featured a patient story and was promoted aggressively through our social media network. In fact, the success of the Gap Promotion provided our first insight into the power of fully engaging our social networking communities. Since the promotion ran for a very limited time, we had to spread the word as quickly and extensively as possible. The Gap Promotion was featured on the @LLS blog and highlighted through

With every support group meeting, with every fundraising event – I’m reminded how powerful my story is and what a source of hope and inspiration it can provide to others. People thank me all the time for sharing my story because I remind them that ‘Cancer Survivors Have Miracles Too.’

The more I give back, the more I’m aware of the importance of doing so – just like Gap!

Commenting on the importance of the Gap Give and Get Promotion to Benefit The Leukemia & Lymphoma Society
I just read your blog. I am so sorry for your loss. I also lost my mom to non-Hodgkin lymphoma 9 years ago.

And I am doing the L.A. Rock ‘n’ Roll half marathon in her honor.

Commenting on a Team Nancy post

---

> **Team Nancy**

Tam Driscoll of Portland, OR had raised funds for LLS’s Team In Training (TNT) for several years. Then, her sister Nancy was diagnosed with an inoperable brain tumor linked to lymphoma and succumbed to the disease in 2009 after a brave six-year battle.

“I realized something wonderful about the power of TNT and LLS. I could see that our actions were helping people survive cancer and would someday lead to a cure. I also realized that alone you can race, but together you can really make a difference.”

Tam persuaded her five other sisters, who live in North Carolina and Virginia, to run with her in the Nike Women’s Marathon to Benefit The Leukemia & Lymphoma Society in San Francisco and raise $40,000 to honor their beloved sister’s memory.

And so Team Nancy was born.

To enhance their fundraising efforts, Tam and her sisters created a TNT Team Nancy eFundraising page where people could make donations online and offer words of encouragement. The sisters also spread the word through their own social media connections, as did other family members and friends.

Their social networking efforts paid off and Team Nancy is well on its way to reaching its fundraising goal.
Congrats! I’m so proud…

to be associated with the Iowa Chapter :).

I’ve been a volunteer with TNT Iowa since 2003 and continue to do events with TNT & LTN (Team Dennis).

The mission of LLS hits close to home. The Iowa Chapter has been a force for good for families throughout the state.

Commenting on the Victory in Iowa post on the LLS Facebook Fan Page

The Dialogue from our Advocacy Community

We have used the power of social media to support several state campaigns and coalition-based efforts to pass legislation that will benefit our patients and their families.

> Victory in Iowa

One such legislation requires health insurance plans to provide routine care coverage (doctor visits, hospital stays, x-rays and lab tests) for cancer patients participating in clinical trials.

Clinical trials are a critical step in the development of new cancer treatments. However, less than 5 percent of adult cancer patients participate in trials, as many insurers consider these studies to be “experimental” and therefore won’t extend coverage. This uncertainty prevents many cancer patients from participating in trials that could aid in their recovery, and makes it difficult for researchers to conduct the studies that might lead to new breakthroughs in cancer cures.
It amazes me…

the possibility of cutting these funds was seriously considered. Cutting funding for cancer research & education is unfathomable.

Everyone on this site has been personally affected by cancer (self-family-friend). Let’s join together & wrestle this beast to improve survivorship & cure possibilities. Thanks.

Post about “Advocacy Network win the Fight to Retain Blood Cancer Education Program”

The LLS Iowa chapter sprung into action when a bill was proposed requiring insurance companies to extend routine medical coverage to patients in clinical trials (House File 2075). Using various social media outlets, the chapter got the word out to patients, family members and volunteers to e-mail their state representatives, urging them to support the bill.

We’re happy to report that our efforts worked. House File 2075 was passed unanimously in both the Iowa House and Senate and in February 2010, Governor Chet Culver signed the bill into law. Several volunteers from the Iowa chapter, including cancer survivors Lorna Johns and Dave Hubler, were on-hand to witness the Governor’s signature. As Dave said at the ceremony: “I am here today because of clinical trials, after other methods had failed.”

People were able to follow this historic day online in real time through updates, photos and video posted on the @LLS Blog, as well as LLS posts on Facebook, Twitter, LinkedIn and Flickr.

Currently, 32 states and the District of Columbia have signed similar bills into law.
Congratulations Dr. Kwak...

for your good work.

Research is key – and always looking for better and newer treatments.

Look forward to seeing the article and will look for it.

Commenting on the LLS blog post, “LLS-Funded Researcher is on Time Magazine’s List of 100 Most Influential People”
2010 Fiscal Year Highlights

On the following pages are examples of the progress we made in 2010 in our mission to cure blood cancers and improve the quality of life of patients and their families.

Patient Information and Services

> Informational Support

Nearly 78,000 inquiries were handled by Masters-level Information Specialists, helping patients navigate the various treatments, clinical trial options and support services.

Over 5,060 clinical trial searches were conducted using Trial Check, a tool that lists available clinical trials by specific blood cancer. Trial Check was created in partnership with the Coalition of Cancer Cooperative Groups.

> Financial Support

More than $14 million was awarded through the LLS Co-Pay Assistance Program to help patients with prescription drug co-pays and insurance premium obligations.

> Educational Support

Over 438,000 patients, caregivers and healthcare professionals attended LLS national telephone/web blood cancer education programs, and nearly 55,000 participants attended community-based LLS chapter blood cancer education programs.

In addition, about 2,600 school personnel, healthcare professionals and parents attended the LLS program Welcome Back Facilitating the School Experience for Childhood Cancer Survivors.

> Community Support

LLS chapters offered 531 family support groups across the US and Canada. Chapter staff and volunteers strengthened their existing relationships and established new ones with more than 636 community-based organizations serving Latino/Hispanic, African-American, rural, and other underrepresented cancer patients.

In all, 32,833 cancer patients and caregivers participated in 479 activities and programs, made possible by the outreach and collaborative efforts of LLS chapters to underrepresented groups across the US and Canada.

In addition, we’re proud to report that 5,376 First Connection matches were made between patients, their family members and trained peer volunteers.

> New Programs

We launched YAconnect – Straight Talk for Young Adults Facing Cancer, a series of programs to help young adults age 18 to 39 deal with “the serious and sometimes absurd” sides of cancer. Weekly moderated online chats were designed for small groups to maximize information sharing among participants.

LLS launched Navigating Employment and Insurance, the first of three YAconnect Web casts, featuring an interactive panel of professionals and young adult cancer survivors.

“YAconnect (www.lls.org/yaconnect) is... a great service for young adults navigating the whole ‘cancer thing’. So nice to see that our age group isn’t forgotten. I know that I will rely on some of the resources provided...as I make the transition from full-time graduate student to jobseeker.”

> YAconnect webcast participant
Grants & Awards
LLS continues to support the development of breakthrough cancer therapies, committing substantial funding to researchers throughout the world. This fiscal year, we reviewed 521 grant applications and granted 99 new awards, including 66 for Career Development and 31 for Translational Research.

Two grants were also given through our Specialized Center of Research (SCOR) initiative, which has provided over $210 million in grants since its inception in 2000. Both recipients have long-time connections to LLS. John C. Byrd, M.D., who first received a grant from LLS in 2001, is targeting molecular processes that allow cancers to evolve and survive today’s standard therapies.

Our second recipient, Brian J. Druker, M.D., first received LLS funding in 1995 that was instrumental in the development of Gleevec as a frontline treatment for patients with chronic myelogenous leukemia (CML). The Druker team continues to develop new targeted therapies, diagnostic tests that can identify which new drug might work best for each patient, and novel clinical trial designs that allow individual patients to receive therapies that best match their disease.

Biotech Alliance Partnerships
LLS partners directly with biotechnology companies to shorten the timeline for identifying potential new cancer therapies and advance them through the FDA drug approval process. This fiscal year, we forged four new biotech company alliances:

Avila > LLS is providing up to $3.2 million for the clinical development of AVL-292 to treat adults with B-cell cancers. The drug entered a clinical trial in September 2010.

FORMA Therapeutics > LLS is partnering with FORMA to develop small molecule compounds to inhibit Bcl-6, a key lymphoma drug target. Approximately 85 percent of non-Hodgkin lymphomas originate from B cells.
LLS Therapy Pipeline: Advancing Therapies through Biotech Partnerships

**Preclinical**
- Laboratory Testing
  - Bcl-6 Inhibitor
  - Epstein Barr Virus Vaccine
  - HDAC Inhibitor

**Phase I**
- Human Safety
  - Lymphoma DLBCL
  - Lymphoma PTLD
  - Cutaneous T-Cell Lymphoma

**Phase II**
- Human Efficacy
  - Antisense Inhibitor
  - Engineered Immuno-therapy
  - Repurposed Drug for Novel Indication
  - BTK Inhibitor

**Phase III**
- Definitive Trial
  - Inhibitor of PI3K/PLK
  - Novel Liposome-based Drug Delivery

**Available to Patients**
- Lymphoma
- Acute Leukemia & AML
- MDS
- CLL / FL
- PTLD
- T-Cell
- Cutaneous Lymphoma
- Lympoma DLBCL
- Lymphoma PTLD
- Cutaneous T-Cell Lymphoma
  - Antisense Inhibitor
  - Engineered Immuno-therapy
  - Repurposed Drug for Novel Indication
  - BTK Inhibitor

**Progress in Clinical Trials**
- **Onconova** > LLS is providing up to $10 million in funding to support the clinical advancement of ESTYBON™ to treat patients with high-risk myelodysplastic syndrome (MDS).
- **Shape Pharmaceuticals** > LLS is providing up to $3.3 million for the clinical development of SHP-141, a first-in-class topical histone deacetylase inhibitor to treat both early- and late-stage cutaneous T-Cell lymphoma (CTCL).

**Onconova** > LLS is providing up to $10 million in funding to support the clinical advancement of ESTYBON™ to treat patients with high-risk myelodysplastic syndrome (MDS).

**Shape Pharmaceuticals** > LLS is providing up to $3.3 million for the clinical development of SHP-141, a first-in-class topical histone deacetylase inhibitor to treat both early- and late-stage cutaneous T-Cell lymphoma (CTCL).

LLS continues to make progress in existing programs with our biotech alliance partners. Celator Pharmaceuticals reported promising results in their phase 2 clinical trial of CPX-351 for older patients with acute myelogenous leukemia (AML), with an impressive 68 percent of patients achieving complete response.

Our alliance partner, Memgen, reported complete response and durable remission for a third of patients in their phase 1 clinical trial of ISF35 for the treatment of chronic lymphocytic leukemia (CLL).

We have also helped advance the drug Ciclopirox Olamine into a phase 1 clinical trial to further its development in the treatment of acute myelogenous leukemia (AML).
We are proud to announce that Team In Training (TNT) has reached an amazing milestone, raising $1 billion through national and local sports events since its inception in 1988.

TNT formalized its longstanding partnership with Competitor Group Inc. (CGI), organizers of the Rock ‘n’ Roll Series events. TNT was designated as the exclusive charity of the renamed Rock ‘n’ Roll San Diego Marathon & 1/2 Marathon to Benefit The Leukemia & Lymphoma Society. The half marathon was added to encourage even more participants in this premier fundraising event. TNT has taken part in the San Diego Marathon since its inception in 1998. This year, we brought over 4,000 participants who raised nearly $12 million to help find cures for blood cancers.

In addition, our goal this year has been to re-engage TNT alumni as higher level volunteers, assisting them in identifying and securing corporate teams to participate with TNT at the national or local level. We also encouraged alumni to serve as fundraising coaches to help TNT participants – especially first-timers – succeed in their fundraising efforts and physical training. This proactive approach to alumni re-engagement has not only introduced new individual, group and corporate sponsors to the program, but has also helped increase overall retention.

**Man & Woman of the Year**

Man of the Year Bob Mills and Woman of the Year Janice Bender had their campaign teams send out letters to potential donors, make personal donation requests, plan events and much more. While Bob and Janice come from different states and professional backgrounds, they both proved the power of teamwork. Together, their campaign teams raised over $500,000. In fact, of the 650 participating candidates, 51 raised enough funds to qualify for the research naming rights incentive.

**School & Youth Programs**

Nearly a quarter of the nation’s schools participated in LLS School & Youth Programs, where students learn the value of working together to raise funds, increase awareness, and make a difference in the fight against cancer. This year, a successful strategy was the distribution of colorful collection boxes for students to take home and collect spare change – a visible reminder for family members to join in the effort and the fun.
Our annual Light The Night Walk raised nearly $39 million in donations, attracting more than 250,000 participants in 218 communities across the US and Canada.

We continued to focus on recruiting more businesses to participate in the program. Walking side by side with our family and friends teams in 2009, more than 82 National Partners raised $6.8 million for LLS research and patient services programs. Setting the standard, once again, was Burlington Coat Factory, our top corporate partner in the Light The Night Walk. This year, they set another milestone by raising more than $2 million for LLS, breaking their previous $1 million mark established in 2007. Burlington Coat Factory has raised over $7 million since our partnership began in 2002.

Legacy & Targeted Giving

This year, we received more than $7 million in legacy gifts from individuals. Several new members were added to The Legacy Circle by naming LLS as a beneficiary in their will, trust, life insurance policy, or retirement plan. These generous individuals have graciously given us permission to list their names so that their gifts can inspire others to do the same.

In addition, we received several Targeted Giving contributions, which will provide much needed support for LLS research and patient programs. For example, when California entrepreneur Steve Kirsch was diagnosed with a rare blood cancer known as Waldenström's macroglobulinemia (WM), he turned to LLS to help find new treatments for this disease. Mr. Kirsch and an anonymous donor joined LLS and the International Waldenström’s Macroglobulinemia Foundation (IWMF) to fund four research grants to develop WM cell lines, a critical link in discovering new and more effective treatments for this currently incurable disease.

The family of Mina Yanney, a 41-year old Pennsylvania investment analyst who died of lymphoma in 2004, had a different idea for their targeted donation. Mina had a strong family network to drive him to treatments at a downtown Philadelphia cancer center. Sadly, many other patients did not and had to drive themselves. In Mina’s honor, his family provided funds to help local cancer patients secure round-trip transportation for their treatments.

The LLS Advocates Network (www.lls.org/advocacy) grew significantly this fiscal year and now numbers nearly 50,000 volunteers. We are working to segment our volunteers for more targeted participation and effective communications.

LLS joined forces with other patient advocacy groups to ensure that national health care reform includes insurance coverage of routine care costs (doctor visits, hospital stays, x-rays, and lab tests) for patients enrolled in clinical trials.

This provision provides a coverage “floor” for state-based insurers, pre-empting state plans that provide fewer patient protections, but also allowing the states to exceed this minimum coverage.

As this provision will impact every type of insurance, state-based legislation is more critical than ever for providing the best patient protections possible.

Advocacy

LLS volunteer advocates in our Florida, Iowa, and South Carolina chapters led coalition efforts to pass state laws ensuring full coverage of routine medical care for cancer patients participating in potentially life-saving clinical trials. This coverage is now required by 32 states and the District of Columbia.

We are also advocating on the state level for laws that provide patients greater access to oral cancer treatments by requiring insurance companies to provide coverage for oral chemotherapy equal to what is covered for intravenous (IV) treatments.
Research Grants

The Marshall A. Lichtman Specialized Center of Research

The Specialized Center for Research Program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD
Walter & Eliza Hall Institute of Medical Research

Frederick Alt, PhD
Immune Disease Institute

Jon Aster, MD, PhD
Brigham & Women’s Hospital

Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

John Byrd, MD
Ohio State University

Riccardo Dalla-Favera, MD
Columbia University

Brian Druker, MD
Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute

Carolyn Felix, MD
The Children’s Hospital of Philadelphia

Anthony Green, MD, PhD
University of Cambridge

James Griffin, MD
Dana-Farber Cancer Institute

Helen Heslop, MD
Baylor College of Medicine

Carl June, MD
University of Pennsylvania

Thomas Kipps, MD, PhD
University of California, San Francisco

Larry Kwak, MD, PhD
University of Texas M.D. Anderson Cancer Center

Ronald Levy, MD
Stanford University

Jonathan Licht, MD
Northwestern University School of Medicine

Scott Lowe, PhD
Cedars-Sinai Medical Center

Beverly S. Mitchell, MD
Stanford University

Stephen Nimer, MD
Memorial Sloan-Kettering Cancer Center

Michael Therian, MD
The University of Chicago

Cheryl Willman, MD
University of New Mexico

Career Development Program

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to leukemia, lymphoma and myeloma research.

Taharman Ahmadi, MD, PhD
University of Pennsylvania

Ioannis Altanisf, PhD
New York University School of Medicine

Arash Alizadeh, MD, PhD
Stanford University

Shannon Anderson, PhD
University of California, San Francisco

Philippe Armand, MD, PhD
Dana-Farber Cancer Institute

Scott Armstrong, MD, PhD
Children’s Hospital Boston

Laura Attard, PhD
Stanford University

Cynthia Barber, PhD
Brandeis University

Craig Bassing, PhD
The Children’s Hospital of Philadelphia

Satarupa Basu, PhD
University of Pennsylvania

Utiya Basu, PhD
Immunology Institute

Michael Begley, PhD
Beth Israel Deaconess Medical Center

Cristian Bellodi, PhD
University of California, San Francisco

Micah Benson, PhD
Harvard Medical School

Avinash Bhandoola, MD, PhD
University of Pennsylvania

Anja-Katrin Bielinsky, PhD
University of Minnesota, Twin Cities

Susan Biggs, PhD
Fred Hutchinson Cancer Research Center

Daniel Billadeau, PhD
Mayo Clinic and Foundation

Debabrata Biswas, PhD
Rockefeller University

Dale Bixby, MD, PhD
University of Michigan

Marie Bleakley, MD
Fred Hutchinson Cancer Research Center

Marzena Blonska, PhD
University of Texas M.D. Anderson Cancer Center

Michael Boddy, PhD
The Scripps Research Institute

Catherine Bolland, MD
Baylor College of Medicine

Niccolo Bolli, MD
Dana-Farber Cancer Institute

Ivan Borrello, MD
Johns Hopkins University School of Medicine

Marina Boussqut, PhD
Whitehead Institute for Biomedical Research

Troy Brady, PhD
University of Pennsylvania

Andrea Bredemeyer, PhD
Brigham & Women’s Hospital

Jennifer Brown, MD, PhD
Dana-Farber Cancer Institute

Claudio Bruneinstein, MD
University of Minnesota, Twin Cities

Lihua Budde, MD, PhD
Fred Hutchinson Cancer Research Center

Gerd Burgart, PhD
Massachusetts General Hospital

Dinis Calado, PhD
Immunology Institute

Kenneth Campellone, PhD
University of California, Berkeley

Pedro Carvalho, PhD
Harvard Medical School

Lucio Castilla, PhD
University of Massachusetts Medical School

Asher Chanan-Khan, MD
Health Research Incorporated, Roswell Park Cancer Institute Division

Jing Chen, PhD
Emory University

Wei-Yi Chen, PhD
Rockefeller University

Xi Chen, PhD
Harvard University School of Public Health

Yi-Bin Chen, MD
Massachusetts General Hospital

Tao Cheng, MD
University of Pittsburgh

Uhn-Soo Cho, PhD
Harvard Medical School

Yoosung Choi, PhD
University of Texas M.D. Anderson Cancer Center

Yuh Min Chook, PhD
University of Texas, Southwestern Medical Center

Eric Chow, MD
Fred Hutchinson Cancer Research Center

Won-Ming Chu, MD, PhD
Brown University

Elaine Chung, PhD
University of Pennsylvania

Maria Giomi, PhD
New York University School of Medicine

Pasquale Cirone, PhD
Yale University

Kenneth Cooke, MD
Case Western Reserve University

Naomi Courtemanche, PhD
Yale University

---

1 Dr. John Byrd is funded in part by Douglas A. and Phyllis Smith, Elaine Smith and Michael and Jacqueline Thomas.
2 Dr. Riccardo Dalla-Favera is funded in part by the Paul E. Singer Family Foundation, Joseph S. and Diane H. Stensberg Charitable Trust, and J.T. Tai & Co. Foundation.
3 Dr. Carolyn Felix is funded in part by The Byers Foundation.
4 Dr. Anthony Green is funded in part by an anonymous donor.
5 Dr. James Griffin is funded in part by the F.M. Kirby Foundation and the Karyn Research Fund.
6 Dr. Thomas Kipps is funded in part by the Silken Valley Community Foundation and an anonymous donor.
7 Dr. Larry Kwak is funded in part by Gerry Gulah.
8 Dr. Ronald Levy is funded in part by Gu and Linda Nahin.
9 Dr. Scott Lowe is funded in part by the Atlasch Foundation/Rasmussen Memorial.
10 Dr. Beverly S. Mitchell is funded in part by the Joseph C. Sanfilippo Memorial Fund and the Harry T. Mungan, Jr. Foundation, Inc.
11 Dr. Michael Therian is funded in part by The Pamela B. Katten Memorial Leukemia Research Foundation, the Allen M. Canell Foundation, Paul and Joan Rutschleg Foundation, the Helen Brach Foundation, The Dr. Ralph and Manus Falk Medical Research Trust, the Kluth Family Foundation, Alberta-Culver Company, The Bohlen Family Foundation and the Kenneth and Angela Paulin Fund.
John Crispino, PhD  
Northwestern University School of Medicine

Vincenzo D’Angiolella, MD, PhD  
New York University School of Medicine

Louise D’Cruz, PhD  
University of California, San Diego

Monique Dail, PhD  
University of California, San Francisco

Mari Dallas, MD  
St. Jude Children’s Research Hospital

Blossom Damania, PhD  
University of North Carolina at Chapel Hill

Michael Davis, PhD  
Fred Hutchinson Cancer Research Center

Renee de Pooter, PhD  
University of Oxford

Michael Deininger, MD, PhD  
Oregon Health & Science University

Ludovic Deriano, PhD  
New York University School of Medicine

Luisa Di Stefano, PhD  
Massachusetts General Hospital

J. Alan Diehl, PhD  
University of Pennsylvania

Chen Dong, PhD  
University of Texas M.D. Anderson Cancer Center

Gregory Driessens, PhD  
The University of Chicago

Jarrod Dudakov, PhD  
St. Jude Children’s Research Hospital

Mary Eapen, MBBS  
Medical College of Wisconsin

Nicholas Endres, PhD  
University of California, Berkeley

Kolja Eppert, PhD  
University Health Network

Michael Farrar, PhD  
University of Minnesota, Twin Cities

Niklas Feldhahn, PhD  
Rockefeller University

David Feldser, PhD  
Massachusetts Institute of Technology

Suhua Feng, PhD  
University of California, Los Angeles

David Ferguson, MD, PhD  
University of Michigan

Adolfo Ferrando, MD, PhD  
Columbia University

Maria Figueroa, MD  
Well Medical College of Cornell University

Noelle Frey, MD  
University of Pennsylvania

Jonathan Friedberg, MD  
University of Rochester

Maxim Frolov, PhD  
University of Illinois, Chicago

Kyriaki Galani, PhD  
Massachusetts Institute of Technology

Boyi Gan, PhD  
Dana-Farber Cancer Institute

Neil Ganem, PhD  
Dana-Farber Cancer Institute

Jason Garrison, PhD  
Bunn Institute for Medical Research

Ulrike Gerdemann, MD  
Baylor College of Medicine

Benjamin Gewurz, MD, PhD  
Bingham & Women’s Hospital

Nilanjan Ghosh, MD, PhD  
Johns Hopkins University School of Medicine

Florent Ginhoux, PhD  
Singapore Immunology Network

Ajay Gopal, MD  
University of Washington

Daniel Gough, PhD  
New York University School of Medicine

Daniel Graham, PhD  
Washington University in St. Louis

H. Leighton Grimes, PhD  
Cincinnati Children’s Hospital Medical Center

Allan Gurtan, PhD  
Massachusetts Institute of Technology

Sara Hamilton, PhD  
University of Minnesota, Twin Cities

Ormid Harandi, PhD  
University of Massachusetts Medical School

Danna Hargrett, PhD  
Princeton University

Jin He, MD, PhD  
University of North Carolina at Chapel Hill

Xi He, PhD  
Children’s Hospital Boston

Jorge Henao-Mejia, MD, PhD  
Yale University

Kiersten Henderson, PhD  
Fred Hutchinson Cancer Research Center

David Hesslein, PhD  
University of California, San Francisco

Elizabeth Hexner, MD  
University of Pennsylvania

Gilles Hickson, PhD  
University of Montreal

Angela Hilliker, PhD  
University of Arizona

Heedeok Hong, PhD  
University of California, Los Angeles

Jian Hu, PhD  
Dana-Farber Cancer Institute

Jian Huang, MD, PhD  
University of Pennsylvania

Yun Huang, PhD  
Immune Disease Institute.

Michael Hudecek, MD  
Fred Hutchinson Cancer Research Center

Madhulika Jain, PhD  
Harvard Medical School

Robert Jenq, MD  
Memorial Sloan-Kettering Cancer Center

Peng Ji, MD, PhD  
Whitehead Institute for Biomedical Research

Emma Josefsson, PhD  
Dana-Farber Cancer Institute

Paweł Juszczyński, MD, PhD  
St. Jude Children’s Research Hospital

Axel Kallies, PhD  
Dana-Farber Cancer Institute

Sumin Kang, PhD  
Ewha Womans University

Tarun Kapoor, PhD  
Rockefeller University

David Kashatus, PhD  
Duke University Medical Center

Barbara Kee, PhD  
The University of Chicago

Younghoon Kee, PhD  
Dana-Farber Cancer Institute

Karen Keeshan, PhD  
University College Cork

TaeSoo Kim, PhD  
Harvard Medical School

Scott Kogan, MD  
University of California, San Francisco

Minooe Kohwi, PhD  
University of Oregon

Motonari Kondo, MD, PhD  
Duke University Medical Center

Mei Kong, PhD  
University of Pennsylvania

Rhett Kowal, PhD  
University of Cincinnati

Maxwell Krem, MD, PhD  
University of Washington

Matthew Krummel, PhD  
University of California, San Francisco

Mijung Kwon, PhD  
Dana-Farber Cancer Institute

James LaBelle, MD, PhD  
Dana-Farber Cancer Institute

Adam Lazorchak, PhD  
Yale University

Sang Eun Lee, PhD  
University of Texas M.D. Anderson Cancer Center

Francene Lemoine, PhD  
Northwestern State University of Louisiana

Gustavo Leone, PhD  
Ohio State University

Anthony Letai, MD, PhD  
Dana-Farber Cancer Institute

Anthony Leung, PhD  
Massachusetts Institute of Technology

Mark Levis, MD, PhD  
Johns Hopkins University School of Medicine

Erin Lew, PhD  
The Salk Institute for Biological Studies

Zachary Lewis, PhD  
University of Oregon

\[\text{Dr. Mark Levis is funded in part by the Douglas Knoll Research Foundation.}\]

\[\text{Dr. Koko Baepons is fully funded by the Stephen Binnbaum Foundation.}\]

\[\text{Dr. Kolja Eppert, a Stephen Binnbaum Scholar, is fully funded by The Stephen Binnbaum Foundation.}\]

\[\text{Dr. Jonathan Friedberg, a Millennium: The Takeda Oncology Company Scholar, is fully funded by Millennium: The Takeda Oncology Company.}\]

\[\text{Dr. Tarun Kapoor is funded in part by The Robert H. Lyon Leukemia Foundation.}\]

\[\text{Dr. Karen Keeshan, a Stephen Binnbaum Scholar, is fully funded by The Stephen Binnbaum Foundation.}\]

\[\text{Dr. Anthony Letai, a Millennium: The Takeda Oncology Company Scholar, is fully funded by Millennium: The Takeda Oncology Company.}\]

\[\text{Dr. Milan Rebloky is funded in part by the knoll Research Foundation and the Rally Foundation for Childhood Cancer Research.}\]

\[\text{Dr. Maria Bousquet is fully funded by the Robert H. Lyon Leukemia Foundation.}\]

\[\text{Dr. Marie Bleakley is funded in part by the Millennium: The Takeda Oncology Company.}\]

\[\text{Dr. Lucía Casteles is funded in part by The Robert H. Lyon Leukemia Foundation and the Remillard Family Foundation.}\]

\[\text{Dr. Suhua Feng is funded in part by Millennium: The Takeda Oncology Company.}\]

\[\text{Newly awarded or renewed grants in fiscal year 2011}\]

\[\text{Dr. Maria Bousquet is funded in part by the Robert H. Lyon Leukemia Foundation and the Rally Foundation for Childhood Cancer Research.}\]
Grants

Shaoguang Li, MD, PhD
University of Massachusetts Medical School

Willis Li, PhD
University of Rochester

Zejuan Li, MD, PhD
The University of Chicago

Zhai Li, MD, PhD
University of Connecticut

Chengyu Liang, MD, PhD
University of Southern California

Sergly Libert, PhD
Massachusetts Institute of Technology

Weili Lin, MD, PhD
University of Alabama at Birmingham

Xin Lin, PhD
University of Texas M.D. Anderson Cancer Center

Allen Liu, PhD
The Scripps Research Institute

Ling Liu, PhD
Stanford University

Mignon Loh, MD
University of California, San Francisco

Simonne Longerich, PhD
Yale University

Sonja Lorenz, PhD
University of California, San Francisco

Li-Fan Lu, PhD
Memorial Sloan-Kettering Cancer Center

Shuo Ma, MD, PhD
Northwestern University School of Medicine

Hiten Madhani, MD, PhD
University of California, San Francisco

Sebastien Malinge, PhD
Northwestern University School of Medicine

Aron Marquitz, PhD
University of North Carolina at Chapel Hill

Daniel Marston, PhD
University of North Carolina at Chapel Hill

Peter Martin, MD
Weill Medical College of Cornell University

William Matsui, MD
Johns Hopkins University School of Medicine

David Matus, PhD
Duke University

Alexander Mazin, PhD
Drexel University College of Medicine

Ari Melnick, MD
Weill Medical College of Cornell University

Joshua Mendell, MD, PhD
Johns Hopkins University School of Medicine

Nam-Sung Moon, PhD
McGill University

Stefanie Mortimer, PhD
University of California, Berkeley

Britta Mueller, PhD
Massachusetts General Hospital

James Mulloy, PhD
Cincinnati Children's Hospital Medical Center

Andrew Mungall, PhD
BC Cancer Agency/British Columbia Cancer Agency

Markus Muschen, MD
Children's Hospital Los Angeles

Anita Nag, PhD
Yale University

Shalin Naik, PhD
The Netherlands Cancer Institute

Shima Nakashishi, PhD
Scripps Research Institute for Medical Research

Geeta Narlikar, PhD
University of California, San Francisco

Jeffrey Nolz, PhD
The University of Iowa

Kristi Norris, PhD
Duke University Medical Center

Leta Nutt, PhD
St. Jude Children's Research Hospital

Christopher Oakes, PhD
Deutsches Krebsforschungszentrum (German Cancer Research Center)

Philipp Oberdoerffer, PhD
Harvard Medical School

Robert Orlovski, MD, PhD
University of Texas M.D. Anderson Cancer Center

Kostas Pajicini, PhD
University of Pennsylvania

Jing Pan, PhD
Memorial Sloan-Kettering Cancer Center

Qishen Pang, PhD
Cincinnati Children's Hospital Medical Center

Dongsu Park, PhD
Massachusetts General Hospital

Danilo Perrotti, MD, PhD
Ohio State University

John Perry, PhD
Stowers Institute for Medical Research

Daniel Polleyea, MD
Stanford University

Christos Polyarchou, PhD
New England Medical Center Hospitals, Inc.

Martin Pric, PhD
University of Washington

Philippe Prochasson, PhD
University of Kansas Medical Center

Thomas Pucadyil, PhD
The Scripps Research Institute

Marc Raaijmakers, MD, PhD
Massachusetts General Hospital

Gunnar Ragnarsson, MD
Fred Hutchinson Cancer Research Center

Noopur Raje, MD
Massachusetts General Hospital

Rajesh Ramachandran, PhD
The Scripps Research Institute

Dale Ramsden, PhD
University of North Carolina at Chapel Hill

Anand Ranjan, PhD
National Cancer Institute

Jeffrey Rathmell, PhD
Duke University Medical Center

Pavan Reddy, MD
University of Michigan

Boris Reizis, PhD
Columbia University

Linda Resar, MD
Johns Hopkins University School of Medicine

Ran Reshef, MD
University of Pennsylvania

Andrey Reya, PhD
University of California, Berkeley

Tannishtha Reya, PhD
Duke University Medical Center

Robin Ricke, PhD
Mayo Clinic and Foundation

David Rizzi, MD
Duke University Medical Center

Edward Rogers, PhD
University of North Carolina at Chapel Hill

Theodora Ross, MD, PhD
University of Michigan

Giovanni Roti, MD
Dana-Farber Cancer Institute

Monideepa Roy, PhD
Bingham & Women's Hospital

James Rubenstein, MD, PhD
University of California, San Francisco

Loredana Ruggeri, MD, PhD
University of Perugia

Davide Ruggiero, PhD
University of California, San Francisco

Laurent Sabbagh, PhD
University of Toronto

Julien Sage, PhD
Stanford University

Sandrine Sander, MD, PhD
Innate Immune Disease Institute.

Karsten Sauer, PhD
The Scripps Research Institute

Aaron Schimmer, MD, PhD
University Health Network

Stephen Schoenberger, PhD
La Jolla Institute for Allergy and Immunology

Dr. Xin Lin is funded in part by an anonymous donor.

Dr. Geeta Narlikar is funded in part by Walter and Beth Grant.

Dr. Qishen Pang is funded in part by The Marge & Charles J. Schott Foundation.

Dr. Danilo Perrotti is funded in part by Charles and Lynda Kraemer and Mark and Christine Kraemer.

Dr. Linda Resar is funded in part by the Cora and John H. Davis Foundation.

Dr. Tannishtha Reya, a Ryan Gibson Foundation Scholar, is partly funded by The Ryan Gibson Foundation.
Baerbel Schroefelbauer, PhD
University of California, San Diego
Suzanne Schubbert, PhD
University of California, Los Angeles
Ralph Scully, MD, PhD
Beth Israel Deaconess Medical Center
Rosalie Seary, PhD
Oregon Health & Science University
Camille Semighini, PhD
Duke University Medical Center
Neil Shah, MD, PhD
University of California, San Francisco
Smita Shankar, PhD
University of California, San Francisco
Sonia Sharma, PhD
Immune Disease Institute
Wei-Jong Shia, PhD
University of California, San Francisco
Warren Shlomchik, MD
Yale University
Erika Shor, PhD
Princeton University
Peter Siciinski, MD, PhD
Dana-Farber Cancer Institute
Robert Signer, PhD
University of Michigan
Jane Sokol, PhD
New York University School of Medicine
Catherine Smith, MD
University of California, San Francisco
Zhou Songyang, PhD
Baylor College of Medicine
Tracy Staton, PhD
Harvard University
School of Public Health
Milan Stojanovic, PhD
Columbia University
Travis Stracker, PhD
Institute for Research in Biomedicine
Matthew Stout, MD, PhD
Yale University
Jason Stumpff, PhD
University of Washington
Kelly Sullivan, PhD
University of Colorado
Wojciech Swat, PhD
Washington University in St Louis
Ivan Topisirovic, MD, PhD
McGill University
Jennifer Trowbridge, PhD
Dana-Farber Cancer Institute
Hsin-yue Tsai, PhD
University of Massachusetts Medical School
Cameron Turtle, MBBS, PhD
Fred Hutchinson Cancer Research Center
Katharine Ullman, PhD
University of Utah
Lidia Vasileva, PhD
Oxford University
Shobha Vasudevan, PhD
Massachusetts General Hospital
Suzanne Vercauteren, MD, PhD
University of British Columbia
Dan Vogl, MD
University of Pennsylvania
Johannes Walter, PhD
Harvard Medical School
Demin Wang, PhD
Blood Research Institute
Gang (Greg) Wang, PhD
Rockefeller University
Lan Wang, PhD
Memorial Sloan-Kettering Cancer Center
Mitchell Weiss, MD, PhD
The Children’s Hospital of Philadelphia
John Welch, MD, PhD
Washington University in St Louis
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center
Sarah Wignall, PhD
Stanford University
Jeremy Wilusz, PhD
Massachusetts Institute of Technology
Petter Woll, PhD
University of Oxford
Jamie Wood, PhD
University of Minnesota, Twin Cities
Tao Wu, PhD
Harvard Medical School
Huaqiang Xie, PhD
Dana-Farber Cancer Institute
Ming Xu, PhD
University of Texas Southwestern Medical Center at Dallas
Jianchang Yang, MD, PhD
Nevada Cancer Institute
Tingting Yao, PhD
Colorado State University
Tong Yin, MD, PhD
Sowers Institute for Medical Research
Carol Ying, PhD
Columbia University
Hoi-Ying (Elsie) Yu, PhD
Brandeis University
Rushdia Yusuf, MD
Massachusetts General Hospital
Shan Zha, MD, PhD
Children’s Hospital Boston
Baochun Zhang, MD, PhD
Immune Disease Institute
Ji Zhang, PhD
University of Pennsylvania
Weiguo Zhang, PhD
Duke University Medical Center
Yaqing Zhang, PhD
University of North Carolina at Chapel Hill
Yu Zhang, PhD
Memorial Sloan-Kettering Cancer Center
Zhiguo Zhang, PhD
Mayo Clinic Foundation
Pengbo Zhou, PhD
Weil Medical College of Cornell University
Zhiwen Zhou, PhD
Harvard Medical School
Yubin Zhou, PhD
Immune Disease Institute
Dimitrios Zisoulis, PhD
University of California, San Diego

Translational Research Program
The Translational Research Program supports outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Albert Baldwin, PhD
University of North Carolina at Chapel Hill
Julio Barreto, MD
University of Miami School of Medicine

Newly awarded or renewed grants in fiscal year 2011

Pamela Becker, MD, PhD
University of Washington
Linda Bendall, PhD
University of Sydney
Ravi Bhattacharya, MD
City of Hope National Medical Center
Smita Bhattacharya, MD
City of Hope National Medical Center
Helen Blau, PhD
Stanford University
Bruce Blazar, MD
University of Minnesota, Twin Cities
Carl Borregaard, PhD
Lund University
Kevin Brindle, PhD
University of Cambridge
John Byrd, MD
Ohio State University
Nicola Camp, PhD
University of Utah
Asher Chan-Chan-Khan, MD
Health Research Incorporated, Roswell Park Cancer Institute Division
Preet Chaudhary, MD, PhD
University of Pittsburgh
Suning Chen, PhD
Jiangsu Institute of Hematology, Soochow University
Wei Chen, MD, PhD
University of Minnesota, Twin Cities
Selina Chen-Kiang, PhD
Weil Medical College of Cornell University
Kent Christopherson, PhD
Rush University Medical Center
Curt Civin, MD
University of Maryland School of Medicine
Michael Cleary, MD
Stanford University
Christopher Cogle, MD
University of Florida
John Crispino, PhD
Northwestern University School of Medicine
Alan D’Andrea, MD
Dana-Farber Cancer Institute

17 Dr. Suzanne Schubbert is funded in part by Parents Against Leukemia.
18 Dr. Neil Shah is fully funded by the Estate of Verna Hoffman.
19 Dr. Weiqiang Shao, a Stephen Benbaum Scholar, is fully funded by The Stephen Benbaum Foundation.
20 Dr. Warren Shlomchik is fully funded by The Newman Family.
21 Dr. Witold Wienda is funded in part by Michelle Henkel, the Silicon Valley Community Foundation and an anonymous donor.
22 Dr. Ming Xu is fully funded by the Dallas Saint Valentine’s Luncheon and Fashion Show.
23 Dr. Pamela Becker is funded in part by the Doug Kloll Research Foundation.
24 Dr. Smita Bhattacharya is funded in part by Mike and Claire Shevin – Links For Leukemia.
25 Dr. John Byrd is funded in part by The Bob Cooper CLI Research Fund, the Silicon Valley Community Foundation and an anonymous donor.
26 Dr. Selina Chen-Kiang is funded in part by the Dallas Saint Valentine’s Luncheon and Fashion Show in memory of Lynda Adleta.
Adolfo Ferrando, MD, PhD
Martin Fernandez-Zapico, MD
Josef Prchal, MD
Celine Gelinas, PhD

George Daley, MD, PhD
Chi Dang, MD, PhD
Utpal Dave, MD
James DeGregori, PhD
Gerald Denis, PhD
Madhav Dhodapkar, MD
Dirk Dittmer, PhD
Gianpietro Dotti, MD
Dimitar Efremov, MD, PhD
Elizabeth Eklund, MD
Thomas Diacovo, MD
Martin Fernandez-Zapico, MD
Adolfo Ferrando, MD, PhD
James Ferrara, MD
Christopher Flowers, MD
Richard Ford, MD, PhD
Mark Frattini, MD, PhD
Celine Gelinas, PhD

Irene Ghobrial, MD
Steven Grant, MD
Jolanta Greimbecka, PhD
Monica Guzman, PhD
Lori Hazlehurst, PhD
Craig Jordan, PhD
Richard Jones, MD
Scott Kaufmann, MD, PhD
Scott Kaufmann, MD, PhD
Tomas Kirchhoff, PhD
Susan Knox, MD, PhD
Jeanne Kowalski, PhD
Donald Kufe, MD
Wen-Hwa Lee, PhD
Suzanne Lentzsch, MD, PhD
Ross Levine, MD
Shaoguang Li, MD, PhD
Daniel Link, MD
Hsiou-Chi Liou, PhD
Mignon Loh, MD
Lawrence Lum, MD, DSC
Nadim Mahmud, MD, PhD
Ari Melnick, MD
David Miljose, MD, PhD
Markus Muschen, MD
Owen O’Connor, MD, PhD
Vivian Oehler, MD
Josef Prchal, MD
Miles Prince, MD
Lee Ratner, MD, PhD
Pavan Reddy, MD
Robert Redner, MD
Robert Orlowski, MD, PhD
Scott Kaufmann, MD, PhD
Tomas Kirchhoff, PhD
Susan Knox, MD, PhD
Jeanne Kowalski, PhD
Donald Kufe, MD
Wen-Hwa Lee, PhD
Suzanne Lentzsch, MD, PhD
Ross Levine, MD
Shaoguang Li, MD, PhD
David Miljose, MD, PhD
Mignon Loh, MD
Lawrence Lum, MD, DSC
Nadim Mahmud, MD, PhD
Ari Melnick, MD
David Miljose, MD, PhD
Markus Muschen, MD

* Newly awarded or renewed grants in fiscal year 2011

* Dr. Adolfo Ferrando is funded in part by Eli Lilly and Company and the Rally Foundation for Childhood Cancer Research.
* Dr. Celine Gelinas is funded in part by Guy Charekko and Guy Del Grande.

**  Newly awarded or renewed grants
Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. Following is a list of the available portfolios and the donors who generously provided support during this fiscal year.

**Acute Lymphocytic Leukemia**
1
**Acute Myeloid Leukemia and Myelodysplastic Syndromes**
2
**Chronic Lymphocytic Leukemia**
3
**Chronic Myelogenous Leukemia**
4
**Hodgkin Lymphoma**
5
**Mantle Cell Lymphoma**
6
**Myeloma**
7
**Aggressive Non-Hodgkin Lymphoma**
8
**Indolent Non-Hodgkin Lymphoma**
9
**Pediatric and Young Adult Blood Cancers**
10
**Quality of Life**
11
**Therapy Acceleration Program**
12
**Waldenstrom Macroglobulinemia Initiative**
13

1  Acute Lymphocytic Leukemia Research Portfolio is funded in part by Deborah Flanagan – Translational Research Program and David and Kim Savage – Megan’s Wings, Inc.
3  Chronic Lymphocytic Leukemia Research Portfolio is funded in part by the American Construction Co., Inc., Helen Anbinder, Stephen and Madeline Anbinder, Brian and Lisa Bee – Spin 4 the Cure, Imagine a Cure for Leukemia, The Jim Jacobs Charitable Foundation, Marilyn and Andrew Lippmann and an anonymous donor.
4  Chronic Myelogenous Leukemia Research Portfolio is funded in part by Rick and Debbie Cox, The Ryan Gibson Foundation, Imagine a Cure for Leukemia, Larry and Leslie Nance and James and Judith Wilson.
5  Hodgkin Lymphoma Research Portfolio is funded in part by Ron and Rasa Kilpatrick.
6  Mantle Cell Lymphoma Research Portfolio is funded in part by Frank Sunberg.
7  Myeloma Research Portfolio is funded in part by the Carlson Family Foundation, Names Family Foundation and the New York State Union of Teachers.
8  Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Creative Escape/ Bazzill Basics Paper, the J.B. Fuqua Foundation, Headstrong Foundation, Poster Family Foundation and The Doug Steele Family – Doug Steele Golf Fore Life Tournament.
9  Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by The Jim Jacobs Charitable Foundation, Timothy and Christine Lindenflether, Jerry and Lois Rosenbloom and an anonymous donor.
10 Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by Brian and Lisa Bee – Spin 4 the Cure, Thomas and Agnes Carvel Foundation, The Jeff Gordon Foundation, Kanyn Research Fund, the Michael W. McCarthy Foundation, Phoenix Partners Group, The Regence Group – In honor of Steven Hooker, Melba Segal and Wawa.
11 Quality of Life Research Portfolio is funded in part by the Hildegarde D. Becher Foundation, Danford Foundation, The Escher Foundation, Greg and Michele Becker, Mike and Kathy Lodra, Hamill Family Trust, McKesson Corporation Foundation, Inc. – In memory of Daniel Berkey, Edward Miner, Ping Y. Tai Foundation, Inc. and an anonymous donor.
12 Therapy Acceleration Program is funded in part by Bruce Bacon, the Peter Burg Memorial Research Fund, The For Julie Foundation, Inc., Frederick and Rosemary Goodwin, John Kolenyi, Patrick and Nancy Mean, Jerry and Lois Rosenbloom, The William J. Shaw Family Foundation and Team Timko.
13 Waldenstrom Macroglobulinemia Initiative is fully funded by Peter Bing, International Waldenstrom Macroglobulinemia Foundation and the Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation.
Medical & Scientific Advisors

Chair
Armand Keating, MD
Princess Margaret Hospital

Vice Chair
Margaret Shipp, MD
Dana-Farber Cancer Institute

Frederick Appelbaum, MD
Fred Hutchinson Cancer Research Center

Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

Alexandra Mayes Birnbaum
PearTree Publishing

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University

Curt I. Civin, MD
University of Maryland School of Medicine

Jorge Cortes, MD
The University of Texas, M.D. Anderson Cancer Center

Brian Druker, MD
Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute

Alan Gewirtz, MD
University of Pennsylvania, School of Medicine

D. Gary Gilliland, MD, PhD
Merck & Co., Inc.

James Griffin, MD
Dana-Farber Cancer Institute

Mary Horowitz, MD
Medical College of Wisconsin

Catriona Jamieson, MD, PhD
University of California, San Diego

Judith Karp, MD
Johns Hopkins Medical Institute

Beverly S. Mitchell, MD
Princess Margaret Hospital

Armand Keating, MD
Johns Hopkins Medical Institute

Beverly S. Mitchell, MD
Stanford University Cancer Research Center

Warren S. Pear, MD, PhD
University of Pennsylvania Abramson Family Cancer Research Institute

The Bill Beattie Memorial Endowment Fund (Alberta)
Mary & Robert Bronstein Memorial Fund
The Virginia Major Brooks Memorial Endowment Fund
de Villiers Endowment Fund
Thomas M. Ford Memorial Fund
GlaxoSmithKline Foundation and GlaxoSmithKline, Inc. Research Fund
Jim Jacobs Leukemia Research Fund
The Rachel Kudish Fund
Jane Elissa/Charlotte Meyers Endowment Fund
The Rae Endowment Fund (Ontario)
Vrushali Ranadive Fellowship Fund
Reich Endowment Fund
The UFCW (Canada) Endowment Fund
## Donors

The below listing is made up of individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

### $1,000,000 and Above
- Burlington Coat Factory
- Celgene Corporation
- Centers for Disease Control and Prevention*
- The Gap Foundation
- Genentech, Inc.
- KGO Newstalk 810 Radio
- The Harry T. Mangurian, Jr. Foundation, Inc.*
- Millennium: The Takeda Oncology Company
- Novartis Pharmaceuticals, Inc.
- Joseph C. Sanfilippo Memorial Fund*
- Paul E. Singer Family Foundation*
- United Food & Commercial Workers Union (UFCW)
- United Food & Commercial Workers International Union (Canada)

### $500,000 – $999,999
- The Beer Store
- Cephalon Oncology
- F.M. Kirby Foundation*
- Susan Lang Foundation*
- The Newman Family*
- The Orokawa Foundation
- Joseph S. and Diane H. Steinberg Charitable Trust*

### $100,000 – $499,999
- Aimers, Inc.
- Austaco, Inc.
- Robert and JoAnna Behl*
- Peter Bing*
- The Stephen Brinbaum Foundation*
- Bristol-Myers Squibb Company
- Peter Burg Memorial Research Fund
- Carter’s, Inc.
- Guy Chiarello
- Citi
- Citrix Systems
- Community Health Charities of New England
- Guy Del Grande
- Dallas Saint Valentine’s Luncheon and Fashion Show
- DialAmerica
- Eliot Systems of America, LLC
- Enzon Pharmaceuticals, Inc.
- Deborah Flanagan*
- GlaxoSmithKline
- The Jeff Gordon Foundation
- The Greene Team
- Estate of Virginia Hoffman
- Imagine a Cure for Leukemia
- International Waldenstrom’s Macroglobulinemia Foundation*
- Jack’s Mannequin – Dear Jack Foundation
- Virginia Sheldon Jerome Foundation
- Pamela B. Katten Memorial Leukemia Research Foundation
- Sydney and Isabel Kemper*
- Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation*
- Neil Kishtr*
- Laborers’ Charitable Foundation
- Rush Limbaugh
- Timothy and Christine Linderfelser*
- The Robert H. Lyon Leukemia Foundation
- Clyde Smith McGregor – in memory of Joan Kaving McGregor
- Michael C. Fina
- Nike
- Nissan
- Novartis Pharma Canada Inc.
- The Olive Garden Italian Restaurant
- Phoenix Partners Group
- PowerBar
- Quest Diagnostics, Inc.
- Richard and Nancy C. Rogers
- Runer’s World
- Salt River Pima-Maricopa Indian Community/Casino Arizona
- Schwinn
- Silicon Valley Bank
- Smigel, Anderson & Saks
- Stater Bros. Markets
- TUAC Québec
- Vistar Corporation
- Wawa
- The Harry & Jeanette Weinberg Foundation, Inc.
- Wells Fargo
- Anonymous (2)

### $50,000 – $99,999
- The KGGI
- Accenture
- Air Products
- Alion Science & Technology
- Allos Therapeutics, Inc.
- American Airlines
- American Electric Power
- AMERICAN SYSTEMS
- Baker-Tilly
- Barclays Capital
- Carlos Batista Foundation
- Bedmar Motorsports
- Big Steaks Management, LLC
- BMC SELECT
- Booz Allen Hamilton
- California Community Foundation
- Carlson Family Foundation*
- Carter’s Babies and Kids
- Cisco Systems, Inc.
- Clif Bar Family Foundation
- Community Health Charities of Florida
- Community Health Charities of Kansas & Missouri
- Cora and John H. Davis Foundation
- Deloitte
- Dominick’s
- Eli Lilly and Company
- Dr. Ralph & Marian Falk Medical Research Trust
- France-Merrick Foundation, Inc.
- Gap, Inc.
- GE Bright Lights
- Genzyme Corporation
- The Ryan Gibson Foundation
- Google
- W.W. Grainger, Inc.
- Walter and Beth Grant*
- Hargrove
- Leon W. (Pete) Harman
- HCA
- Betty Ruth and Milton Hollander
- Teresa J. Huber
- Industrial Alliance
- Innovative Event Production (IEP)
- Johnson & Johnson
- Karyn Research Fund*
- Kiere Media, LLC
- Lighthouse Investment Partners, LLC
- Lunardi’s Markets
- Michael W. McCarthy Foundation
- James and Patricia McPherson
- Microsoft Corporation
- Mills Family Foundation
- The Offerdinger Family
- PhRMA
- PricewaterhouseCoopers LLP
- Regence BlueCross BlueShield*
- The Victor E. and Caroline E. Schutte Foundation – Trust E
- Michael Sheehy
- Siemens
- Sigma Alpha Epsilon Fraternity, University of Georgia
- Silicon Valley Community Foundation
- Carol Stilwell*
- Team Timko
- Paul Towu
- Toyota
- TRIB Total Media
- Trust
- United Way of the National Capital Area
- Vario Energy Foundation
- The Valley Foundation
- Washington Area Mercedes-Benz Dealers
- Wilson Farms, Inc.
- Anonymous (1)

### $10,000 – $49,999
- 7-Eleven
- 97.1 WASH-FM
- AAPI of Central Ohio
- ACS, A Xerox Company
- Ann Adams
- Howell and Madeline Adams, Jr., – In memory of Madeline Adams
- Adobe
- Aegis
- Aetna Foundation
- AIG Highstar
- AK Steel Foundation
- Alaska Airlines
- Alberto-Culver Company

* Denotes multi-year commitment
Donors

Beckloff Associates
Brian and Lisa Bee – Spin 4 the Cure
The Beeerman Foundation
Stefan Belanick Legacy Fund
The Bell Family Foundation
Bell Microproducts
The Belvedere Cove Foundation
BERT SMITH & Co.
Best Brands Corporation
BET Networks
The BGR Foundation, Inc.
BGR Group
Bierman, Geesing & Ward, LLC
Clyde and Rosie Billman
Bingham McCutchen, LLP
Alexandra Mayes Bimbaum
Bill and Nicki Black
Philip Black
The Blackstone Charitable Foundation
Blue Moon Fund
Blue Shield of California
The Blumenfeld Family
BNY Mellon
The Boardwalk
Bruce Bocina
Boeing Employees Community Fund
Bognar & Company, Inc.
Herman and Emmie Bolden
Boston Millenium Partners
BP
BP Fabric of America Fund
Michael Bradley
Ronald M. Bradley Foundation
Helen Brach Foundation
Brass-Craft
Brayton Purcell
The Breden-Adams Foundation
Brewers of Indiana Guild, Inc.
The Eli and Edythe Broad Foundation
Peter and Janice Brock
Broaward Health
The Brown Family
Brown & Gould, LLP
The Bryce Foundation
BT
Building Hope
Eileen Burg
Burnham Family Foundation
Burston-Marsteller
Butler Family Foundation
CA, Inc.
John Cademartori
Anthony and Deborah Campbell
Campbell & Company
Samuel C. Cantor Charitable Trust
CapitalSource
Capitol Broadcasting Company
Capitol File Magazine
CareFirst BlueCross BlueShield
CARFAX, Inc.
James Carmack
Don and Linda Carter
Carter BloodCare
The Center For Executive Development, Inc.
Central Blood Bank
Centric Bank
CFACQ
CGI Group, Inc.
CGI Federal
CH2M Hill
Central Blood Bank
Central
CFACQ
CGI Group, Inc.
CGI Federal
CH2M Hill
Harvey Chaplin
The Rhoda and David Chase Family Foundation
Chemel Kornick & Company, LLC
The Children’s Mercy Hospital
Chil Media Inc.
Cintas
Citigroup Corporate and Investment Banking
The Classic Catering People
Cleary Gottlieb Steen & Hamilton, LLP
Bruce and Isabel Cleland
Cleveland Indians Baseball Company
CNO
The Cobalt Foundation, Inc.
Columns Resource Group Foundation, Inc.
Combined Health Agencies
Comcast
Commerce Bank
Community Blood Center
The Community Foundation for the National Capital Region
Community Health Charities of Alabama
Community Health Charities of Arizona
Community Health Charities of Colorado
Community Health Charities of Georgia
Community Health Charities of Illinois
Community Health Charities of Iowa
Community Health Charities of Kentucky
Community Health Charities of Maryland
Community Health Charities of Michigan
Community Health Charities of Minnesota
Community Health Charities of New York
Community Health Charities of Texas
Community Health Charities of the National Capital Area
Community Health Charities of Virginia
Computer Aid, Inc.
The Bob Cooper CLL Research Fund
Alverin M. Cornell Foundation
Costa Wholesale
The Meredith A. Cowden Foundation
Rid de Dobby Cox
Richard Cox
Creative Escape/Bazzill Basics Paper
Credit Suisse
Credit Suisse Americas Foundation
The Cramar Foundation
Crave Horwath, LLP
Cruise Industry Charitable Foundation
Dahntun For The Cure, LLC
Dana-Farber Cancer Institute
Danford Foundation
Randy and Deborah Daniel Family Charitable Foundation
DARCARS
The Danish Family
Donald and Leena Davis
Davis-Moore Auto Group
DC Rental
Del Monte Foods
Del Inc.
Delta Energy, LLC
Alcaldes & Fay
Alchemy Brewers Association
Allegis Group
Alliance Data
Alliance Holdings, Inc.
The Alsop Foundation – Reichman Memorial
Alyssa’s Crew
American Construction Co., Inc.
American Electric Power
America’s Charities
America’s Health Insurance Plans (AHIP)
Helen Anbinder
Stephen and Madeline Anbinder
Shaya Ansari
Anthem Insurance Companies, Inc.
Apothe Corporation
The Apatow Family Foundation, Inc.
Apache Corporation
Argonne National Laboratory
Arizona Public Service
ATR International
AutoTrader.com
Aweso
Charles Baker
Baker Botts, LLP
Tim Banazek
Banc of America Securities, LLC
Bank of America
Bank of Tokyo – Mitsubishi UFJ, Ltd.
Donna Baran
Barclays Bank Delaware
Barefoot Wine & Bubbly
Bartimus Frickleton Robertson & Gorry
Carol Bartz
BASF, The Chemical Company
Stephen Bauer
Bay Family Foundation
BBVA Compass Bank
Hildegarde D. Becher Foundation, Inc.
The Bill Bernbach Foundation
BD Biosciences
The Bill Bernbach Foundation
Broward Health
The Eli and Edythe Broad Foundation
Cleveland Indians Baseball Company
CNO
The Cobalt Foundation, Inc.
Columns Resource Group Foundation, Inc.
Combined Health Agencies
Comcast
Commerce Bank
Community Blood Center
The Community Foundation for the National Capital Region
Community Health Charities of Alabama
Community Health Charities of Arizona
Community Health Charities of Colorado
Community Health Charities of Georgia
Community Health Charities of Illinois
Community Health Charities of Iowa
Community Health Charities of Kentucky
Community Health Charities of Maryland
Community Health Charities of Michigan
Community Health Charities of Minnesota
Community Health Charities of New York
Community Health Charities of Texas
Community Health Charities of the National Capital Area
Community Health Charities of Virginia
Computer Aid, Inc.
The Bob Cooper CLL Research Fund
Alverin M. Cornell Foundation
Costa Wholesale
The Meredith A. Cowden Foundation
Rid de Dobby Cox
Richard Cox
Creative Escape/Bazzill Basics Paper
Credit Suisse
Credit Suisse Americas Foundation
The Cramar Foundation
Crave Horwath, LLP
Cruise Industry Charitable Foundation
Dahntun For The Cure, LLC
Dana-Farber Cancer Institute
Danford Foundation
Randy and Deborah Daniel Family Charitable Foundation
DARCARS
The Danish Family
Donald and Leena Davis
Davis-Moore Auto Group
DC Rental
Del Monte Foods
Del Inc.
Delta Energy, LLC
Alcaldes & Fay
Alchemy Brewers Association
Allegis Group
Alliance Data
Alliance Holdings, Inc.
The Alsop Foundation – Reichman Memorial
Alyssa’s Crew
American Construction Co., Inc.
American Electric Power
America’s Charities
America’s Health Insurance Plans (AHIP)
Helen Anbinder
Stephen and Madeline Anbinder
Shaya Ansari
Anthem Insurance Companies, Inc.
Apothe Corporation
The Apatow Family Foundation, Inc.
Apache Corporation
Argonne National Laboratory
Arizona Public Service
ATR International
AutoTrader.com
Aweso
Charles Baker
Baker Botts, LLP
Tim Banazek
Banc of America Securities, LLC
Bank of America
Bank of Tokyo – Mitsubishi UFJ, Ltd.
Donna Baran
Barclays Bank Delaware
Barefoot Wine & Bubbly
Bartimus Frickleton Robertson & Gorry
Carol Bartz
BASF, The Chemical Company
Stephen Bauer
Bay Family Foundation
BBVA Compass Bank
Hildegarde D. Becher Foundation, Inc.
The Bill Bernbach Foundation
BD Biosciences
The Bill Bernbach Foundation
Broward Health
The Eli and Edythe Broad Foundation
Cleveland Indians Baseball Company
CNO
The Cobalt Foundation, Inc.
Columns Resource Group Foundation, Inc.
Combined Health Agencies
Comcast
Commerce Bank
Community Blood Center
The Community Foundation for the National Capital Region
Community Health Charities of Alabama
Community Health Charities of Arizona
Community Health Charities of Colorado
Community Health Charities of Georgia
Community Health Charities of Illinois
Community Health Charities of Iowa
Community Health Charities of Kentucky
Community Health Charities of Maryland
Community Health Charities of Michigan
Community Health Charities of Minnesota
Community Health Charities of New York
Community Health Charities of Texas
Community Health Charities of the National Capital Area
Community Health Charities of Virginia
Computer Aid, Inc.
The Bob Cooper CLL Research Fund
Alverin M. Cornell Foundation
Costa Wholesale
The Meredith A. Cowden Foundation
Rid de Dobby Cox
Richard Cox
Creative Escape/Bazzill Basics Paper
Credit Suisse
Credit Suisse Americas Foundation
The Cramar Foundation
Crave Horwath, LLP
Cruise Industry Charitable Foundation
Dahntun For The Cure, LLC
Dana-Farber Cancer Institute
Danford Foundation
Randy and Deborah Daniel Family Charitable Foundation
DARCARS
The Danish Family
Donald and Leena Davis
Davis-Moore Auto Group
DC Rental
Del Monte Foods
Del Inc.
Delta Energy, LLC

<table>
<thead>
<tr>
<th>Delta Health Systems</th>
<th>Grace J. Fippinger Foundation</th>
</tr>
</thead>
<tbody>
<tr>
<td>John DeRosa</td>
<td>Fishing Bay Yacht Club, Inc.</td>
</tr>
<tr>
<td>Deutsche Bank</td>
<td>Fitzgerald Family Foundation</td>
</tr>
<tr>
<td>DeWaxy Capital Management</td>
<td>Jodie Flint</td>
</tr>
<tr>
<td>Diagnostic and Interventional Spinal Care</td>
<td>Foley &amp; Lardner LLP</td>
</tr>
<tr>
<td>Diplomat Country Club and Spa</td>
<td>The Beverly M. Folger Foundation</td>
</tr>
<tr>
<td>Dive N’ Surf</td>
<td>The For Julie Foundation, Inc.</td>
</tr>
<tr>
<td>DLA Piper, LLP (US)</td>
<td>FxSider</td>
</tr>
<tr>
<td>Dominion Foundation</td>
<td>John &amp; Mary Franklin Foundation</td>
</tr>
<tr>
<td>Dominion Homes</td>
<td>David Frantz</td>
</tr>
<tr>
<td>Dominion Resources, Inc.</td>
<td>Fraser High School</td>
</tr>
<tr>
<td>Christopher Darr Memorial</td>
<td>Laurel Friedman</td>
</tr>
<tr>
<td>Duff &amp; Phelps</td>
<td>Friends of Heroes</td>
</tr>
<tr>
<td>Duquesne Light Corporation</td>
<td>Freeze Harley-Davidson Ride</td>
</tr>
<tr>
<td>E.P. Vaughan Beneficiaries, U.S. Bank Private Client Group</td>
<td>Paul N. Frimmer, Esq.</td>
</tr>
<tr>
<td>Edkert Seamans Cherin &amp; Mellott, LLC</td>
<td>Catherine Fugazy</td>
</tr>
<tr>
<td>EdVoyles Automotive Group</td>
<td>Fulbright &amp; Jaworski, LLP</td>
</tr>
<tr>
<td>EFESTE Winery</td>
<td>Furniture Fair</td>
</tr>
<tr>
<td>James L. Eichberg Foundation, Inc.</td>
<td>Mrs. Dorothy C. Fuqua</td>
</tr>
<tr>
<td>Steven Eisenstadt</td>
<td>J.B. Fuqua Foundation</td>
</tr>
<tr>
<td>Elite Fitness Systems</td>
<td>G&amp;T Sports Medicine</td>
</tr>
<tr>
<td>Elliott Bay Marina</td>
<td>Courtney Knight Gaines Foundation, Inc.</td>
</tr>
<tr>
<td>Ellsworth Corporation</td>
<td>Galen College of Nursing</td>
</tr>
<tr>
<td>Embassy Suites Hotel Monterey Bay</td>
<td>Garden City Turkey Trot Race Committee</td>
</tr>
<tr>
<td>Emergent BioSolutions, Inc.</td>
<td>Garden Court Hotel</td>
</tr>
<tr>
<td>Emerson Motor Technologies</td>
<td>Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td>Enzo Pharmaceuticals</td>
<td>GE Capital</td>
</tr>
<tr>
<td>Energy Enterprise Solutions, LLC</td>
<td>GE Foundation</td>
</tr>
<tr>
<td>The Enrichment Foundation</td>
<td>GEICO</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>GEICO Philanthropic Foundation</td>
</tr>
<tr>
<td>Enterprise Rent-A-Car</td>
<td>General Dynamics C4 Systems, Inc.</td>
</tr>
<tr>
<td>Epsilon Data Management, LLC</td>
<td>General Dynamics Information Technology</td>
</tr>
<tr>
<td>Endo Pharmaceuticals</td>
<td>Georgia Power Foundation, Inc.</td>
</tr>
<tr>
<td>Enderley Corporation</td>
<td>R.M. Gerstacker Foundation</td>
</tr>
<tr>
<td>Embassy Suites Hotel Monterey Bay</td>
<td>GetWellNetwork, Inc.</td>
</tr>
<tr>
<td>Emergent BioSolutions, Inc.</td>
<td>Gila River Gaming Enterprises</td>
</tr>
<tr>
<td>Emerson Motor Technologies</td>
<td>Peter and Ann Gilbert</td>
</tr>
<tr>
<td>Enzo Pharmaceuticals</td>
<td>Goat Brothers</td>
</tr>
<tr>
<td>Energy Enterprise Solutions, LLC</td>
<td>Sheila Gold Foundation</td>
</tr>
<tr>
<td>The Enrichment Foundation</td>
<td>Goldman, Sachs &amp; Co.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Gerry Golub</td>
</tr>
<tr>
<td>Enterprise Rent-A-Car</td>
<td>John Goodish</td>
</tr>
<tr>
<td>Epsilon Data Management, LLC</td>
<td>Frederick and Rosemary Goodwin</td>
</tr>
<tr>
<td>Endo Pharmaceuticals</td>
<td>Great American Insurance Group</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Great Harvest Franchising, Inc.</td>
</tr>
<tr>
<td>Enterprise Rent-A-Car</td>
<td>Theodore and Debra Green</td>
</tr>
<tr>
<td>Epsilon Data Management, LLC</td>
<td>Greenberg Traurig, LLP</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Guarenteed Rate</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>H&amp;R Block</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Hamit Family Trust</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Handley Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Harbins Builders</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Haugh Family Charitable Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>HB Group Insurance Management Ltd.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Headstrong Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>HealthOne</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Jim Healy</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Heartland Health</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Heils Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Hendin Family</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Michelle Henkel</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Timothy Henkel</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Herbert Homes, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Heritage Bag Company</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Highmark BlueCross BlueShield</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Lester and Ellen Hightower</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Phil and Wendy Hildebrand</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>HITT Contracting, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Freddie Hoffman</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Hogan &amp; Hartson, LLP</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Holland &amp; Knight</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Holt Lunsford Commercial Real Estate, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Michelle Lunn Hope Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Horizon Foundation for New Jersey</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Howard Family Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Howrey, LLP</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Howsworth Blood Center</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>HSBC Bank USA, N.A.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Human Genome Sciences, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Humana, Inc. – Great Lakes Region</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Bruce &amp; Priscilla Hutchins Family Legacy Endowment</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Hy-Vee, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>IBM Employee Services Center</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>ICAP Services North America, LLC</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>In Memory of Dixie Shadow</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>In Memory of Maxwell Mason Jewell Independent Health</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Infinity Technology LLC</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Insulators Health Hazard Fund</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Investment Technology Group, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Investors Group Charitable Giving Program</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>J.T.Tai &amp; Co. Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Jim Jacobs Charitable Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Jared Coones Pumpkin Run/Walk</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>JDP Mechanical, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>JFK Medical Center Foundation, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The John Theurer Cancer Center at Hackensack University Medical Center</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Violet M. Johnson Family Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Ralph and Sally Jones</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Just Give</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Gerald Kafka and Rita Cavanagh</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kaiser Permanente</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Daniel and Susan Kane</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Karchs Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Gary and Rochelle Katz</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Steven Kaufmann</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Kaufman Family Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Keane Group Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Christopher Keans</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>John Kellenyi</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>David and Susie Kelley</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Douglass R. Kenny and Family</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kent Family Charitable Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kent’s 5K Run</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>John and Carol Kerins</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kettering Health Network</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Key Banc Capital Markets</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kia Motors of America</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Ron and Rosie Kilpatrick</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>King &amp; Spalding, LLP</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>David Kirtz</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Klein Family Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kluth Family Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kohls</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Kolache Factory</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Arthur Kontos Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>KPMG LLP</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Charles and Lynda Kraemer</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Mark and Christine Kraemer</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Kraft Foods, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Jeannette and H. Peter Kriendler Charitable Trust</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Krichman Family Foundation, Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Kroger Co.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Douglas Kroll Research Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>The Kutz Foundation</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>KST Data Inc.</td>
</tr>
<tr>
<td>Enterprise Holdings Foundation</td>
<td>Mike and Kathy Ladra</td>
</tr>
</tbody>
</table>

* Denotes multi-year commitment
Donors

Laffey McHugh Foundation
Linda LaGanga
Diane S. Lake Family
Marie Lamont Charitable Foundation
Lanier Parking Solutions
Bombardier Learjet Employees Care Fund
Lisa Leder
John Lefebvre
The Len-Ari Foundation, Inc.
Les Détérimés
Les Invincibles
Steven Lieblitch
LifeSource
Lightner Sams Foundation, Inc.
Carl Linhner
Marlene and Andrew Lippmann
List Innovative Solutions
Donajean Littrell
Peter and Tina Locke
Lockheed Martin Corporation
Peter and Tina Locke
Dorajean Littrell
List Innovative Solutions
Marlene and Andrew Lippmann
Carl Lindner
Lightner Sams Foundation, Inc.
Lisa Leder
Care Fund
Bombardier Learjet Employees Care Fund

McFeen Foundation
Casey McGlynn
Sean and Erin McGould
McKesson Corporation Foundation, Inc.
McKinsey & Company, Inc.
McKinnis, Inc.
The Gerald and Paula McNichols Family Foundation
Meadow Gardens Ladies Invitational Golf Tournament
MedAssets
MedImmune
The Memorial Foundation
Memorial Healthcare System
Merkes Development, Inc.
Merk & Co., Inc.
Meredith Corporation Foundation
Metro Waste
MicroLink, LLC
Microsoft Corporation/Federal Systems Division
Microsoft Matching Gifts Program
The Mifsud Family
Mike Hunter’s Team
Pam Miller
James Miligan
Patrick and Nancy Minan
Edward Miner
Suzy Minnoff
MIQ Logistics
Mission Foods Corporation
Mizuho Corporate Bank, Ltd.
MLB Advanced Media, LP
Lori Mody
Monster Mechanical, Inc.
Moody Foundation
Morgan Borszcz Consulting
Morgan Stanley
Morgan Franklyn Corporation
Jonathan Morris
Antone Munfa
Murray & Guari
Joseph Naggar
The Najim Family Foundation
Names Family Foundation
Larry and Leslie Nance
Nartel Family Foundation

The Nassi Group, LLC
National Cooperative Services Corporation
National Rural Utilities Cooperative Finance Corporation
NBC5
Thomas Neill
Nestle Purina
NetApp
The Netter Foundation
NewYork Community Bancorp, Inc.
New York State Union of Teachers
Kenneth and Bonni Newton
Nicholas Family Foundation
Guy and Linda Nohra
Northrop Grumman
Northside Hospital
Northwestern Mutual Foundation
Norton Cancer Institute
NRG Energy, Inc.
Morgan O’Brien
Occidental Petroleum Corporation
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Old Westbury Golf & Country Club
Oncology Center of Central Baltimore
The W. O’Neil Foundation
Onyx Pharmaceuticals, Inc.
Oracle
Osprey Foundation
OU Medicine
Betty Owens
Oxford Development
Dave and Patti Pace
Palmetto Ford
The Pampered Chef
Parents Against Leukemia
Park Place Motorcars Dallas
Peoples Health
Peoples Natural Gas
Peoples Health
Peoples Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health
People’s Health

Pittsburgh Pirates
Plaid Pantries, Inc.
Planned Systems International
PNC Bank
PNC Bank Foundation
Polo Ralph Lauren Foundation
Antonio B. and Rita M. Pomerleau Foundation, Inc.
Dave and Teri Peral
Poster Family Foundation
Powell Industries
Prairie Farms Dairy
Prairie Meadows
The Pry Family Foundation
PRDC
John and Monika Preston
Price Modern, LLC
Protiviti, Inc.
Providence Alaska Medical Center
Puysullap Tribe of Indians
Rabobank
Ralph Helming Trust of 2008
Rally Foundation for Childhood Cancer Research
Stuart and Barbara Ray
Raytheon Company
RBC Capital Markets
RBC Foundation
Redall Financial
Regence
The Regence Group
– In honor of Steven Hooker
Francis X. and Susan Reinhardt
Robert Zeitkes
Remillard Family Foundation
James Resnick
Reznick Group
Riemer & Braunstein, LLP
Risen & Inch
Rite Aid Corporation
RMD Corporation
AI Roadburg Foundation
Robert Michael Communications, Inc.
Edith Roberts
Eddie Robinson
Roth Robinson
Rocky Mountain Blood and Marrow Transplant Program
The Drew Rodriques Foundation
Peter and Lynn Rogers
Rogers Family Foundation
The Rogers Foundation
The Theodore Rosenberg Charitable Foundation
Jerry and Lois Rosenberg
Matt Rosenthal
Sandra Rosenthal
Amanda Ross
Royal Bank of Canada
The Royal Bank of Scotland
Royals Charities
RR Donnelley
RREEF
Paul and Joan Rubschlager Foundation
The Ruby Restaurant Group
Rural Telephone Finance Cooperative
Christopher Russell
Jeff and Pat Sachs
John Salata
Salesforce.com Foundation
Salle Mae, Inc.
The San Francisco Foundation
Sandisk
Sandra Atlas Bass Foundation
Samford University
Sanofi Aventis
Santa Clara Marriott
Sanofi U.S.
Shawver Family
Scharff, Inc.
The Charles H. and Rachel M. Scharff Foundation
Sheehy Lexus of Annapolis
The Sidney and Harriet M. Scheyman Foundation
The Schellenberg Foundation
The Schott Foundation
Shevlin Technologies, LLC
Foundation
The Victor E. and Caroline E. Schutte Foundation
– Megan’s Wings, Inc.
The Earl and Brenda Shapiro Foundation
Kevin Shannahan
Shadowitz Family and Friends
Sewell Cadillac
Angelo and Anne Settembrini
Serco, Inc.
Isador S. Segall Trust
Melissa Segal*
Sedano’s Supermarkets
Searcy Denney Scarola Barnhart & Shipley, PA
Sedano’s Supermarkets
Sedano’s Supermarkets
Sedano’s Supermarkets
The Marge & Charles J. Schott Charitable Foundation
Blake Sheltan
Mike and Claire Shevelin – Links For Leukemia
The Sheltan Family Foundation
Siebert Brandford Shank & Co., LLC
Simmonds Family Foundation
The Sidney, Milton & Leoma Simon Foundation
Douglas A. and Phyllis Smith
Elaine Smith
Smith Productions
Kevin Sneader
Seizer Against Leukemia & Lymphoma
Gloria Somerville Wagner
Sony, Inc.
Southeast Nebraska Hematology & Oncology
SouthWest Bank
Spangenberg Family Foundation
John W. & Effie E. Speas Memorial Trust
Sprint Corporation
Mark and Carol Spiszak
Sprint
SRA International
St. Joseph’s Candler
St. Luke’s Mountain States Tumor Institute
St. Vincent de Paul Foundation, Inc.
Stanley Konshak
State of New York Department of Health
The Doug Steele Family – Doug Steele Golf Fore Life Tournament
Stephanie Walker Fund
John Stewart
Ken and Ann Stinson
Stinson, Morrison, Hecker LLP
Structure Tone, Inc.
Sun Dun, Inc. of Washington
Frank Sunberg
Harry Sunenshine
SunTrust Bank
SUPERVALU
SureTec
Susan Mott Webb Charitable Trust
Sweet Ovations
Michael Sweng
Swinging for a Cure
Syringa Networks
Symex America, Inc.
T-Wall Properties
Shen Tackett
Target Corporation
Targeting Lymphoma Shoot
Brian and Diana Taussig
TBD Foundation, an advised fund of the Silicon Valley Community Foundation
TDS Metrocom
Team Chad
Team EMC
Team Luca
Technology Concepts & Design, Inc.
Texas Instruments Marketing Group – In Memory of Raj Gupta
Texas Roadhouse
Rick and Susan Theider
Michael and Jacqueline Thomas
Gillis and Bille Thomas
Rodney Thompson
Thompson Habib Denison (THD)
Becca Cason Thrash
Edgar A. Thronson Foundation, Inc.
Thunderbirds Charities
Tiber Creek Partners, LLC
Title Associates
Too Hot To Trot
Towers Watson
Trainor Wine & Spirits
Trans-Siberian Orchestra
Transwestern
James Triantos
Triton Harbarding Service
Truland Service Corporation
Truland Service Corporation
Triton Harbarding Service
Truland Service Corporation
Trump Entertainment
Igor Tygiansky
Tube City IMS
Turner Interiors
Jack A. Turpin
U.S. Bank
U.S. Bank Private Client & Trust Services
UBS Securities, LLC
Unanet Technologies
Unisys Corporation
United Space Alliance, LLC
United States Steel Corporation
UnitedHealthcare
University of Pittsburgh Medical Center
Valley Jewelry & Loan
Joseph and Drenda Vijuk
The Vons Foundation
Wachovia Wells Fargo Foundation
Waddell & Reed Kansas City Marathon
Denny and Diana Walker
Washington Area Toyota Dealers Association, Inc.
Washington Business Journal
Washington Gas
The Washington Post & Cars.com
WASHINGTONIAN
The Watkins Family
Waverly Meegan, LLC
Wawanesa Insurance Company
Lisa Weber
Wehner/Marsico Associates
The Stone and Holt Weeks Foundation
Wendy’s of Michigan
West Penn Allegheny Health System
Westchester Tri-Team
The Frederick and Margaret L. Weyerhaeuser Foundation
Wheeler Family Charitable Foundation
Charlie and Shelly Whetzel
White Castle
WiLine Networks
Brett Williams
Mark and Sharon Williams
James and Judith Wilson
Winston & Strawn, LLP
WVTB-TV, Channel 4
Richmond and Kaye Wolff
Woodbine Entertainment Group
The Carl M. Woolford Foundation, Inc.
Toledo Blade
WTOP Radio
WUSA9
Wyeth Pharmaceuticals
Daniel Wyner
Wyse Technology
The Yahoo Employee Foundation
Mina Yanney
Eric and Tamara Yollick
Young Hearts
John and Adelaide Zabriskie
Ziolkowski Patent Solutions Group
Joseph Zvesper
Anonymous (10)

* Denotes multi-year commitment
Top Campaign Fundraisers
Individuals who have raised more than $50,000 or company teams that have raised more than $100,000 to support LLS’s mission.

Rose Astorina
Austaco, Inc.
Carolyn Balling
Barclays Capital
Jack Beckman
Janice Bender*
The Blackstone Group
The Blumenfeld Family
Burlington Coat Factory
Annie Calbiano
Carter’s Babies and Kids
Hope Cherry
Citi
Citrix Systems
Coach, Inc.
Andy Collins
Jenna Kirke Crandell
Credit Suisse
Dan Darby & Band Against Blood Cancer
Jim Davis
Deloitte
Delta Energy, LLC
Tam Driscoll
Lisa Dunn
Frances Duprey
Elbit Systems of America, LLC
Ashley Erickson
Evelyn Erives & On Air Care
Ernst & Young LLP
Joey Fago
Darin Ferguson
Cary Fishburne
James Fitzgerald
Alexandra Freyberg & PC Commandos
Sean Geiger & Raising Hope
Georgia Chain Gang
Georgia Pest Control Association
Katherine G. Guiffre
The Greene Team
Mary Helferstedt
Michelle Henkel
Josh Horowitz
Kiven, Katler; Lieberman, Fox, Joffe, Goldschmidt & Kepes Team
Jack’s Mannequin – Dear Jack Foundation
Travis Janovich
Daniel S. Johnson
Joseph B. Kelley
William Kenny
Thomas Klein
Ryan LaFontaine
Michael Lapicki
Daniel S. Laski
Dr Alan Lichtin
Steven Lily
Rabin Lineberger
The Lymphomaniacs
J. David Mahoney
David Mammina
James Marchewka
Edye McCarthy
Mary McLaughlin & The BELIEVE Campaign
Justin McMaster
Lance Meyerovich
Michael C. Fina
Bob Mills*
Marc Moore
Sarah Moore
Steve Movius
Pat Mazursky
Novartis
Ed Offherringer
Lisa Pagano & Stand Up Take Notice
Steve Paschos
Quest Diagnostics, Inc.
Steve Richburg
The Riders of the Storm
Mary Kathryn Rodrigue
Katie Rost & Team Believe
Joe Sadowski
Jared Salvetti
Silicon Valley Bank
Yuliya Singo
Ted St. Pierre
Stater Bros. Markets
Peter Strang
Fernando Suarez
Jadlyn Toll
Vin Torma
Valero Energy Corporation
Vistar
Brad T. Wagner
Elizabeth Wahler
Dr. Stanley Walker
Martha Whitecotton
Beth R. Wiesner
Yahoo
Dr. Zimmerman

* National Man & Woman of the Year

Legacy Circle honors those who name LLS in their wills, or as beneficiaries of a trust, retirement account or insurance policy or enter into a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Irene Ambrosius*
Lorraine Arazak*
Louise Barrows*
Melvin Baum*
Ray and Anna Bergren*
Andrew and Edith Berto*
Alyce Bigia*
Samuel and Eleanor Bjorkman*
Edward and Christina Blanchard
Camille Blok
Michael Boyne*
Elizabeth Brady
Marcia Brown*
Hester Joyce Burtenshaw*
Roger Busch*
Coy and Lucille Byerly*
Jean Carlisle*
John Carlson*
Ira Weiner

* National Man & Woman of the Year

Deceased
The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (LLS) as of June 30, 2010, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of LLS’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from LLS’s 2009 consolidated financial statements and, in our report dated September 15, 2009, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of LLS’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2010, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

September 15, 2010
New York, New York
## Consolidated Statement of Financial Position

The Leukemia & Lymphoma Society, Inc. > June 30, 2010
(With comparative amounts at June 30, 2009) (In thousands)

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$21,196</td>
<td>$28,196</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>4,577</td>
<td>4,314</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>130</td>
<td>75</td>
</tr>
<tr>
<td>Legacies and contributions receivable, net (note 2)</td>
<td>18,417</td>
<td>22,752</td>
</tr>
<tr>
<td>Investments (note 3)</td>
<td>177,489</td>
<td>161,623</td>
</tr>
<tr>
<td>Fixed assets, less accumulated depreciation and amortization of $7,965 and $12,544</td>
<td>5,132</td>
<td>4,616</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$226,941</td>
<td>$221,576</td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Liabilities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$16,448</td>
<td>$14,682</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>16,940</td>
<td>15,479</td>
</tr>
<tr>
<td>Grants payable (notes 4 and 5)</td>
<td>80,580</td>
<td>85,768</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>113,968</td>
<td>115,929</td>
</tr>
</tbody>
</table>

#### Net assets (note 9):

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>88,617</td>
<td>78,551</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>20,668</td>
<td>23,596</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,688</td>
<td>3,500</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>112,973</td>
<td>105,647</td>
</tr>
</tbody>
</table>

### Total liabilities and net assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$226,941</td>
<td>$221,576</td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
# Consolidated Statement of Activities

**The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010**

(With summarized totals for the year ended June 30, 2009) (In thousands)

## Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$247,939</td>
<td>$31,885</td>
<td>$84</td>
<td>$279,908</td>
<td>$291,521</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(36,635)</td>
<td>–</td>
<td>–</td>
<td>(36,635)</td>
<td>(39,077)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>211,304</td>
<td>31,885</td>
<td>84</td>
<td>243,273</td>
<td>252,444</td>
</tr>
<tr>
<td>Legacies</td>
<td>4,045</td>
<td>3,009</td>
<td>–</td>
<td>7,054</td>
<td>26,459</td>
</tr>
<tr>
<td>Donated services (note 1)</td>
<td>6,819</td>
<td>–</td>
<td>–</td>
<td>6,819</td>
<td>6,829</td>
</tr>
<tr>
<td>Net interest and dividend income (note 3)</td>
<td>4,351</td>
<td>53</td>
<td>26</td>
<td>4,430</td>
<td>6,467</td>
</tr>
<tr>
<td>Net increase (decrease) in fair value of investments</td>
<td>11,238</td>
<td>19</td>
<td>78</td>
<td>11,335</td>
<td>(7,315)</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>1,897</td>
<td>–</td>
<td>–</td>
<td>1,897</td>
<td>2,768</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>37,894</td>
<td>(37,894)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>277,548</td>
<td>(2,928)</td>
<td>188</td>
<td>274,808</td>
<td>287,652</td>
</tr>
</tbody>
</table>

## Expenses (note 10)

### Program Services:

- Research                                                                   | 70,910       | –                      | –                     | 70,910     | 69,786 |
- Patient and community service                                              | 83,406       | –                      | –                     | 83,406     | 93,448 |
- Public health education                                                     | 41,597       | –                      | –                     | 41,597     | 41,331 |
- Professional education                                                      | 8,073        | –                      | –                     | 8,073      | 8,497  |

- **Total program services**                                                 | 203,986      | –                      | –                     | 203,986    | 213,062|

### Supporting Services:

- Management and general                                                     | 22,462       | –                      | –                     | 22,462     | 23,259 |
- Fund raising                                                                | 41,255       | –                      | –                     | 41,255     | 43,132 |

- **Total supporting services**                                              | 63,717       | –                      | –                     | 63,717     | 66,391 |

**Total expenses**                                                           | 267,703      | –                      | –                     | 267,703    | 279,453|

## Change in net assets before foreign currency translation adjustment

| Description                                                                 | 9,845        | (2,928)                | 188                   | 7,105      | 8,199  |

## Foreign currency translation adjustment

| Description                                                                 | 221          | –                      | –                     | 221        | (648)  |

## Change in net assets

| Description                                                                 | 10,066       | (2,928)                | 188                   | 7,326      | 7,551  |

## Net Assets

| Description                                                                 | 78,551       | 23,596                 | 3,500                 | 105,647    | 98,096 |

| End of year                                                                 | $88,617      | $20,668                | $3,688                | $112,973   | $105,647|

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010  
(With comparative totals for the year ended June 30, 2009) (In thousands)

### Program Services

<table>
<thead>
<tr>
<th></th>
<th>Research</th>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants</td>
<td>$58,714</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>$58,714</td>
</tr>
<tr>
<td>Therapy acceleration program (note 6)</td>
<td>8,227</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>8,227</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>– 6,059</td>
<td>$ –</td>
<td>$ 6,059</td>
<td>$ –</td>
<td>6,059</td>
</tr>
<tr>
<td>Co-pay assistance (note 5)</td>
<td>– 14,003</td>
<td>$ –</td>
<td>$ 14,003</td>
<td>$ –</td>
<td>14,003</td>
</tr>
<tr>
<td>Donated services</td>
<td>1,054</td>
<td>$ 5,785</td>
<td>$ 6,059</td>
<td>$ 6,059</td>
<td>6,059</td>
</tr>
<tr>
<td>Salaries</td>
<td>1,339</td>
<td>$ 27,758</td>
<td>$ 15,886</td>
<td>$ 4,191</td>
<td>15,886</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 7)</td>
<td>223</td>
<td>$ 7,612</td>
<td>$ 4,929</td>
<td>$ 1,258</td>
<td>4,929</td>
</tr>
<tr>
<td>Occupancy (note 8)</td>
<td>40</td>
<td>$ 3,378</td>
<td>$ 2,363</td>
<td>$ 631</td>
<td>2,363</td>
</tr>
<tr>
<td>Insurance</td>
<td>10</td>
<td>$ 212</td>
<td>$ 159</td>
<td>$ 28</td>
<td>159</td>
</tr>
<tr>
<td>Telephone</td>
<td>36</td>
<td>$ 1,844</td>
<td>$ 1,036</td>
<td>$ 167</td>
<td>1,036</td>
</tr>
<tr>
<td>Travel</td>
<td>48</td>
<td>$ 754</td>
<td>$ 549</td>
<td>$ 139</td>
<td>549</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>183</td>
<td>$ 2,707</td>
<td>$ 5,901</td>
<td>$ 378</td>
<td>5,901</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>15</td>
<td>$ 705</td>
<td>$ 486</td>
<td>$ 124</td>
<td>486</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>18</td>
<td>$ 993</td>
<td>$ 3,676</td>
<td>$ 140</td>
<td>3,676</td>
</tr>
<tr>
<td>Meetings</td>
<td>423</td>
<td>$ 2,396</td>
<td>$ 753</td>
<td>$ 204</td>
<td>753</td>
</tr>
<tr>
<td>Professional fees</td>
<td>567</td>
<td>$ 7,430</td>
<td>$ 4,731</td>
<td>$ 509</td>
<td>4,731</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>6</td>
<td>$ 1,100</td>
<td>$ 672</td>
<td>$ 204</td>
<td>672</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>27</td>
<td>$ 670</td>
<td>$ 456</td>
<td>$ 100</td>
<td>456</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$70,910</strong></td>
<td><strong>$83,406</strong></td>
<td><strong>$41,597</strong></td>
<td><strong>$8,073</strong></td>
<td><strong>$203,986</strong></td>
</tr>
</tbody>
</table>

### Supporting Services

<table>
<thead>
<tr>
<th></th>
<th>Research</th>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
<td>$ –</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$58,714</strong></td>
<td><strong>$63,542</strong></td>
<td><strong>$58,714</strong></td>
<td><strong>$58,714</strong></td>
<td><strong>$58,714</strong></td>
</tr>
</tbody>
</table>

### Direct donor Benefit costs

<table>
<thead>
<tr>
<th></th>
<th>Research</th>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$70,910</strong></td>
<td><strong>$83,406</strong></td>
<td><strong>$41,597</strong></td>
<td><strong>$8,073</strong></td>
<td><strong>$203,986</strong></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th></th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>26.5%</td>
</tr>
<tr>
<td>Patient and Community Service</td>
<td>31.2%</td>
</tr>
<tr>
<td>Public Health Education</td>
<td>15.5%</td>
</tr>
<tr>
<td>Professional Education</td>
<td>3.0%</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td><strong>76.2%</strong></td>
</tr>
<tr>
<td>Management and General</td>
<td>8.4%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>15.4%</td>
</tr>
<tr>
<td><strong>Total Supporting Services</strong></td>
<td><strong>23.8%</strong></td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Cash Flows

*The Leukemia & Lymphoma Society, Inc. > Year ended June 30, 2010*  
*(With comparative amounts for the year ended June 30, 2009) (In thousands)*

### Cash flows from operating activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>$7,326</td>
<td>$7,551</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash used in operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net (increase) decrease in fair value of investments</td>
<td>$(11,335)</td>
<td>7,315</td>
</tr>
<tr>
<td>Permanently restricted revenue collected</td>
<td>(84)</td>
<td>(119)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>1,780</td>
<td>1,717</td>
</tr>
<tr>
<td>Increase in allowance for uncollectible accounts</td>
<td>415</td>
<td>413</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>(263)</td>
<td>493</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(55)</td>
<td>1,285</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>3,920</td>
<td>(15,998)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>1,766</td>
<td>(6,018)</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>1,461</td>
<td>(1,695)</td>
</tr>
<tr>
<td>Grants payable</td>
<td>(5,188)</td>
<td>4,098</td>
</tr>
<tr>
<td><strong>Net cash used in operating activities</strong></td>
<td>$(257)</td>
<td>$(958)</td>
</tr>
</tbody>
</table>

### Cash flows from investing activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchases of fixed assets</td>
<td>(2,296)</td>
<td>(1,185)</td>
</tr>
<tr>
<td>Purchases of investments</td>
<td>(119,968)</td>
<td>(186,225)</td>
</tr>
<tr>
<td>Sales of investments</td>
<td>115,437</td>
<td>180,265</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>$(6,827)</td>
<td>$(7,145)</td>
</tr>
</tbody>
</table>

### Cash flows from financing activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permanently restricted contributions collected</td>
<td>84</td>
<td>119</td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>84</td>
<td>119</td>
</tr>
</tbody>
</table>

Net decrease in cash and cash equivalents:  
(7,000) | (7,984) 
Cash and cash equivalents at beginning of year:  
28,196 | 36,180 
**Cash and cash equivalents at end of year**:  
$21,196 | $28,196

See accompanying notes to consolidated financial statements.
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. > June 30, 2010
(with comparative amounts as of and for the year ended June 30, 2009)

1. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (LLS) is an international not-for-profit health agency dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin’s disease, and myeloma and improving the quality of life of patients and their families. LLS’s principal activities include: awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood cancer information made to LLS’s Information Resource Center; and disseminating educational information about blood cancers in the form of publications, internet sites, conference calls, and symposia sponsorship for both the medical community and the general public.

Tax-Exempt Status
LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly-supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and, is therefore, not subject to income taxes if certain disbursement requirements are met.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of LLS, which encompasses the Home Office of LLS and its fifty-five chapters in the United States, LLSC, and LLS’s not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc. and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

Estimates
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, the allowance for uncollectible accounts, and the allocation of expenses. Actual results could differ from those estimates.

Risks and Uncertainties
LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the statement of financial position.

Summarized Financial Information
The consolidated financial statements are presented with 2009 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2009 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2009 consolidated financial statements from which the summarized information was derived.

Subsequent Events
LLS evaluated subsequent events after the statement of financial position date of June 30, 2010 through September 15, 2010, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period or purpose.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Foreign Currency Translation
LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact of the translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 inputs are unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent) (ASC 820), for certain alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

Most investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate fair value of LLS’s interest therein, its classification in Level 2 or 3 is based on LLS’s ability to redeem its interest at or near June 30. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services
LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. Specifically, the donated services of family support group facilitators and research grant reviewers in the amount of $6,819,000 in 2010 and $6,829,000 in 2009 have been valued and are reported as both revenue and expense.

Cash Equivalents
Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held for long-term purposes reported as investments.
Investments
Investments are stated at fair value based upon quoted market prices, except for the fair values of funds of hedge funds and limited partnerships, which are based on net asset values provided by the fund managers and general partners, respectively, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, if purchased, or at fair value at date of donation, if contributed; and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter.

Recent Accounting Standards
In 2010, LLS adopted ASC 740, Accounting for Uncertainty in Income Taxes. LLS evaluated the impact of adopting the accounting and disclosure requirements of ASC 740 for uncertainties in income taxes recognized in the consolidated financial statements, which prescribes a threshold of more-likely-than-not for recognition and de-recognition of tax positions taken or expected to be taken in a tax return. There was no significant impact to LLS’s consolidated financial statements as a result of the adoption of ASC 740.

2. Legacies and Contributions Receivable
LLS’s legacies and contributions receivable at June 30, 2010 and 2009 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$16,675</td>
<td>$21,154</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>3,157</td>
<td>2,334</td>
</tr>
<tr>
<td>After 5 years</td>
<td>232</td>
<td>208</td>
</tr>
<tr>
<td>Subtotal</td>
<td>20,064</td>
<td>23,696</td>
</tr>
<tr>
<td>Less allowance for uncollectible accounts</td>
<td>(1,164)</td>
<td>(749)</td>
</tr>
<tr>
<td>Less discount to present value (5%)</td>
<td>(483)</td>
<td>(195)</td>
</tr>
<tr>
<td>Total</td>
<td>$18,417</td>
<td>$22,752</td>
</tr>
</tbody>
</table>

Approximately 54% and 60% of LLS’s legacies and contributions receivable are from one estate at June 30, 2010 and 2009, respectively.

3. Investments
The following table presents LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2010 and 2009 (in thousands):

<table>
<thead>
<tr>
<th>Description</th>
<th>2009 Level 1</th>
<th>2009 Level 2</th>
<th>2009 Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$1,514</td>
<td>$1,514</td>
<td>$ –</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income</td>
<td>64,162</td>
<td>64,162</td>
<td>–</td>
</tr>
<tr>
<td>Low duration fixed income</td>
<td>49,216</td>
<td>49,216</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>3,490</td>
<td>3,490</td>
<td>–</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>9,817</td>
<td>9,817</td>
<td>–</td>
</tr>
<tr>
<td>All cap equity</td>
<td>1,932</td>
<td>1,932</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>5,772</td>
<td>5,772</td>
<td>–</td>
</tr>
<tr>
<td>Small cap equity</td>
<td>6,394</td>
<td>6,394</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>1,023</td>
<td>1,023</td>
<td>–</td>
</tr>
<tr>
<td>Alternative investments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funds of hedge funds</td>
<td>4,148</td>
<td>2,000</td>
<td>–</td>
</tr>
<tr>
<td>Limited partnership equity indices</td>
<td>14,155</td>
<td>–</td>
<td>14,155</td>
</tr>
<tr>
<td>Total</td>
<td>$161,623</td>
<td>$145,320</td>
<td>$16,303</td>
</tr>
</tbody>
</table>

Investment expenses of $580,000 and $568,000 have been netted against interest and dividend income for the years ended June 30, 2010 and 2009, respectively. The unrealized gains and losses were $10,344,000 and $(5,923,000) for the years ended June 30, 2010 and 2009, respectively.

LLS invests in certain alternative investments, through “funds of hedge funds” investments, which invest in multiple strategies through a portfolio of hedge fund managers to provide diversification and reduce manager risk. These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

The underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 70 to 90 days. As of June 30, 2010, the following table summarizes the composition of such investments at fair value by the various redemption provisions (in thousands):

<table>
<thead>
<tr>
<th>Redemption Period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly</td>
<td>$13,003</td>
</tr>
<tr>
<td>Quarterly</td>
<td>17,461</td>
</tr>
<tr>
<td>1 year lock-up</td>
<td>15,992</td>
</tr>
<tr>
<td>Total</td>
<td>$46,456</td>
</tr>
</tbody>
</table>

As of June 30, 2010 and 2009, LLS has no unfunded commitments on its alternative investments.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2010 and 2009 (in thousands):

<table>
<thead>
<tr>
<th>Description</th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at July 1</td>
<td>$16,303</td>
<td>$19,334</td>
</tr>
<tr>
<td>Purchases</td>
<td>15,750</td>
<td>2,000</td>
</tr>
<tr>
<td>Investment expense</td>
<td>(131)</td>
<td>(103)</td>
</tr>
<tr>
<td>Investment income</td>
<td>–</td>
<td>322</td>
</tr>
<tr>
<td>Net increase (decrease) in fair value</td>
<td>286</td>
<td>(5,260)</td>
</tr>
<tr>
<td>Transfers to Level 2</td>
<td>(16,216)</td>
<td>–</td>
</tr>
<tr>
<td>Balance at June 30</td>
<td>$15,992</td>
<td>$16,303</td>
</tr>
</tbody>
</table>

The Leukemia & Lymphoma Society
Notes to Consolidated Financial Statements  Continued

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by LLS’s Board of Directors. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. In addition to unconditional grants payable of $80,580,000 at June 30, 2010, LLS has grant commitments of $67,433,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Co-Pay Assistance Program

The Co-Pay Assistance program offers assistance to patients in meeting their insurance co-pay obligations for prescription medications or public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Approximately $4,374,000 and $7,448,000 were included in the grants payable balances for amounts awarded but unpaid at June 30, 2010 and 2009, respectively.

6. Therapy Acceleration Program (TAP)

TAP is LLS’s strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $22,230,000 at June 30, 2010 and that are conditioned upon future events and, accordingly, are not recorded.

7. Pension Plan

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. Expense under this plan aggregated $4,072,000 and $4,105,000 for the years ended June 30, 2010 and 2009, respectively.

LLS has a 457(b) deferred compensation plan (the 457 Plan), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plan approximated $120,000 and $170,000 for the years ended June 30, 2010 and 2009, respectively. The assets and liabilities of the 457 Plan are included in investments and accounts payable in the accompanying consolidated statement of financial position and amounted to approximately $546,000 and $437,000 at June 30, 2010 and 2009, respectively.

8. Lease Commitments

The leases for premises, which LLS’s Home Office and chapters occupy, expire on various dates through May 31, 2016 and provide for certain payments subject to escalation and periodic increases relating to real estate taxes, operating expenses, and utilities. The Home Office lease expires in March 2016. The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ 7,502</td>
<td>$ 6,814</td>
<td>$ 5,139</td>
<td>$ 4,285</td>
<td>$ 3,889</td>
<td>$ 2,920</td>
<td>$ 30,549</td>
</tr>
</tbody>
</table>

9. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2010 and 2009 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time restrictions</td>
<td>$ 12,344</td>
<td>$ 16,566</td>
<td>$ 28,910</td>
</tr>
<tr>
<td>Research</td>
<td>3,983</td>
<td>2,241</td>
<td>6,224</td>
</tr>
<tr>
<td>Patient service</td>
<td>4,180</td>
<td>4,658</td>
<td>9,838</td>
</tr>
<tr>
<td>Other</td>
<td>161</td>
<td>131</td>
<td>292</td>
</tr>
<tr>
<td>Total</td>
<td>$ 20,668</td>
<td>$ 23,596</td>
<td>$ 44,264</td>
</tr>
</tbody>
</table>

LLS follows the Uniform Management of Institutional Funds Act (UMIFA), LLS has interpreted UMIFA as requiring the preservation of the original gift of the donor-restricted endowment fund absent donor stipulations to the contrary. In September 2010, New York State adopted the Uniform Prudent Management of Institutional Funds Act. In 2011, LLS will be required to adopt the net asset classification requirements of ASC 958-205, Endowments of Not-for-Profit Organizations: Net Asset Classification of Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act, and Enhanced Disclosures for All Endowment Funds.

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2010 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$ 1,396</td>
<td>$ 397</td>
<td>$ 3,500</td>
<td>$ 5,293</td>
</tr>
<tr>
<td>Investment (expense) income</td>
<td>(74)</td>
<td>65</td>
<td>104</td>
<td>95</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>473</td>
<td>–</td>
<td>–</td>
<td>473</td>
</tr>
<tr>
<td>Contributions</td>
<td>–</td>
<td>–</td>
<td>84</td>
<td>84</td>
</tr>
<tr>
<td>Net assets released</td>
<td>100</td>
<td>(100)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>$ 1,895</td>
<td>$ 362</td>
<td>$ 3,688</td>
<td>$ 5,945</td>
</tr>
</tbody>
</table>

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2009 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$ 2,198</td>
<td>$ 635</td>
<td>$ 3,079</td>
<td>$ 5,912</td>
</tr>
<tr>
<td>Investment income</td>
<td>43</td>
<td>76</td>
<td>9</td>
<td>128</td>
</tr>
<tr>
<td>Net (depreciation) appreciation</td>
<td>(710)</td>
<td>(161)</td>
<td>5</td>
<td>(866)</td>
</tr>
<tr>
<td>Contributions</td>
<td>–</td>
<td>–</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td>Net assets released</td>
<td>153</td>
<td>(153)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Redesignation of net assets</td>
<td>(288)</td>
<td>–</td>
<td>288</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>$ 1,396</td>
<td>$ 397</td>
<td>$ 3,500</td>
<td>$ 5,293</td>
</tr>
</tbody>
</table>

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift.

Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

10. Joint Costs Allocation

For the years ended June 30, 2010 and 2009, LLS incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$ 12,114</td>
<td>$ 12,834</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,049</td>
<td>1,013</td>
</tr>
<tr>
<td>Public health education</td>
<td>10,537</td>
<td>10,188</td>
</tr>
<tr>
<td>Total</td>
<td>$ 23,700</td>
<td>$ 24,035</td>
</tr>
</tbody>
</table>

34
National Leaders

Chairman of the Board
Steven L. Hooker
The Regence Group
Portland, OR

Vice Chair
Scott Carroll
Jackson Lewis
Cincinnati, OH

Secretary/Treasurer
Kevin R. Ryan
Citin Cooperman & Company, LLP
Philadelphia, PA

Board of Directors
James A. Beck
Hefren-Tilottson, Inc.
Butler, PA

Alexandra Mayes Birnbaum
Peartree Communications, Inc.
New York, NY

Robert A. “Spider” Cantley
Twin Harte, CA

Elizabeth Clark, PhD, MPH, ACSW
National Association of Social Workers
Washington, DC

Jorge Cortes, MD
The University of Texas M.D. Anderson Cancer Center
Houston, TX

James H. Davis, PhD, JD
Human Genome Sciences, Inc.
Rockville, MD

Timothy Durst
Baker Botts LLP
Dallas, TX

Thomas L. Fitzpatrick
Saint Gobain Corporation
Worcester, MA

David Frantze
Sinari, Morrison Hecker LLP
Kansas City, MO

Paul N. Frimmer
Loeb & Loeb, LLP
Los Angeles, CA

Alan M. Gewirtz, MD
University of Pennsylvania
School of Medicine
Philadelphia, PA

D. Gary Gilliland, MD
Merck
North Wales, PA

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

John M. Kamins
Faster, Swift, Collins & Smith, PC
Farmington Hills, MI

Armand Keating, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Marie Lauria, MSW
Chapel Hill, NC

Steven Lilly
NRLCFC
Herndon, VA

Rodman N. Myers
Honigman Miller Schwartz and Cahn
Detroit, MI

Norbert J. Sieber
NJS Consultants
Miami, FL

Jay L. Silver
Sugar Land, TX

Mary Simmonds, MD
New Cumberland, PA

Thomas R. Snyder
Nashville Bank and Trust
Nashville, TN

William M. Ward, Jr.
Presbyterian Manors of Mid-America
Wichita, KS

Louise Warner
Chagrin Falls, OH

Kathryn West, RN, MSN, OCN
Amgen
Thousand Oaks, CA

Michele Wong
Synergex International Corporation
Gold River, CA

President &
Chief Executive Officer
John E. Walter

Chief Mission Officer
Research & Scientific Programs
Louis DeGennaro, PhD

Chief Marketing
& Revenue Officer
Nancy L. Klein

Chief Financial Officer
Jimmy Nangle

Senior Vice President
Chief Information Officer
Jeff Como

Senior Vice President
Public Policy
George Dahlman

Senior Vice President
Patient Services
Hildy Dillon

Senior Vice President
Human Resources
Philip Kozlowski

Senior Vice President
Field Development
George Omiros

Senior Vice President
Revenue Generation
Michael Osso

Senior Vice President
Volunteer Engagement
David Timko

The Leukemia & Lymphoma Society of Canada

President
Nancy Allen
Chapter
Offices

Alabama
100 Chase Park South, Suite 220
Birmingham, AL 35244
205.989.0098

Arizona
3877 North 7th Street, Suite 300
Phoenix, AZ 85014
602.567.7600

California
340 West Falsbrooke Avenue, Suite 101
Fresno, CA 93711
559.435.1482
6033 West Century Boulevard, Suite 300
Los Angeles, CA 90045
310.342.5800
765 The City Drive South, Suite 260
Orange, CA 92868
714.818.5600
2143 Hurley Way, Suite 110
Sacramento, CA 95827
916.941.7120
4530 West Fallbrook Avenue
San Diego, CA 92123
858.277.1800
372 Danbury Road
303.984.2110
Denver, CO 80227
Suite 400
5353 West Dartmouth Avenue
Colorado 80227
408.490.2666

Connecticut
372 Danbury Road, Suite 200
Wilton, CT 06897
203.665.1400

Delaware
100 West 10th Street, Suite 209
Wilmington, DE 19801
302.661.7300

Florida
2 Oakwood Boulevard, Suite 200
Hollywood, FL 33020
954.744.5300

Georgia
3715 Northside Parkway
Building 400 Northside Drive, Suite 300
Atlanta, GA 30327
404.720.7900

Illinois
651 West Washington Boulevard
Suite 400
Chicago, IL 60661
312.631.7350

Indiana
941 East 86th Street, Suite 100
Indianapolis, IN 46240
317.726.2270

Iowa
8033 University Boulevard
Des Moines, IA 50325
515.277.6169

Kansas
6811 West 63rd Street
Overland Park, KS 66202
913.266.1515
300 North Main Street, Suite 300
Wichita, KS 67202
316.266.4050

Kentucky
301 East Main Street, Suite 100
Louisville, KY 40202-1077
502.584.8490

Maryland
11350 McCormick Road
Baltimore, MD 21210
410.891.1999

Massachusetts
9 Erie Drive, Suite 101
Natick, MA 01760
508.810.1300

Michigan
1421 East Twelve Mile Road, Suite 100
Warren, MI 48071
586.944.3514

Minnesota
8441 Wayzata Boulevard, Suite 340
Golden Valley, MN 55426
763.852.3000

Mississippi/Louisiana
3636 South 1-10 Service Road
Suite 304
Natchez, MS 76001
504.837.9049

Missouri
1220 South 27th Street
St. Louis, MO 63118
314.878.0780

Nebraska
10832 Old Mill Road, Suite 200
Omaha, NE 68154
402.344.2242

New Jersey
14 Commerce Drive, Suite 303
Cranford, NJ 07016
908.956.6608

New Mexico
341 N Candalaria NE, Suite M
Albuquerque, NM 87107
505.872.0141

New York
5 Computer Drive West, Suite 100
Albany, NY 12205
518.438.3593
4053 Maple Road
Amherst, NY 14226
716.834.2578
555 Broad Hollow Road, Suite 403
Melville, NY 11747
631.752.8500
475 Park Avenue South, 8th Floor
New York, NY 10016
212.376.7100
1311 Mamaroneck Avenue, Suite 130
White Plains, NY 10605
914.949.0084

North Carolina
401 Harrison Oaks Boulevard, Suite 200
Cary, NC 27513
919.367.4100

Ohio
2300 Wall Street, Suite H
Cincinnati, OH 45212
513.361.2100
2297 Commerce Park
Cleveland, OH 44122
216.910.1200
225 City Gate Drive, Suite E
Columbus, OH 43219
614.476.7194

Ohio
1200 South Avenue, Suite 102
Columbus, OH 43219
614.476.7194

Pennsylvania
555 North Lane Drive, Suite 300
Conshohocken, PA 19428
610.238.0777
800 Corporate Circle, Suite 100
Harrisburg, PA 17110
717.652.6520
333 East Carson Street, Suite 441
Pittsburgh, PA 15219
412.395.2873

Rhode Island
416.581.9541

Texas
8111 LBJ Freeway, Suite 122
Dallas, TX 75251
972.996.5900
5005 Mitchell Drive, Suite 115
Houston, TX 77092
713.680.8088
950 Iowan Road, Suite 125
San Antonio, TX 78216
210.377.1775

New Mexico
341 N Candalaria NE, Suite M
Albuquerque, NM 87107
505.872.0141

North Carolina
401 Harrison Oaks Boulevard, Suite 200
Cary, NC 27513
919.367.4100

Virginia
551 S Staples Mill Road, Suite 202
Richmond, VA 23228
804.627.0400

Washington
530 Dexter Avenue North, Suite 300
Seattle, WA 98109
206.628.0777

Wisconsin
200 South Executive Drive, Suite 203
Brookfield, WI 53005
262.790.4701

Canada
Canada Corporate
804-2 Lansdowne Square
Toronto, ON M3J 4P8
416.661.9541 x104

British Columbia Region
310-1682 West 7th Avenue
Vancouver, BC V6J 1G6
604.733.2873

Québec Region
705-1255 University Street
Montreal, QC H3B 3W1
514.875.1000

Ontario Region
1502-480 University Avenue
Toronto, ON M5G 1V2
416.585.2873

Atlantic Region
2020-10th Street NW
Calgary, AB T2M 3M2
403.263.5300
The Leukemia & Lymphoma Society

is a nonprofit organization that relies on the generosity of individual, foundation and corporate contributions to advance its mission.